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Summary 
 
Tick-borne encephalitis virus (TBEV) is a member of the genus Flaviviruses, family 
Flaviviridae and contains a single stranded (ss) RNA genome with positive polarity.  
Innate immunity is important to recognize viral structures and control viral replication 
of RNA viruses. Mammalian cells provide pathogen recognition receptors (PRRs) to 
detect products of viral replication and to trigger signal cascades, which result in the 
establishment of an antiviral state by the induction of type I interferons (IFNs). 
Here, we investigated the interaction of TBEV with the host innate immune system. In 
particular, we were interested in the role of type I interferons on TBEV infections in 
vitro and on mechanisms leading to IFN activation.  
We showed that infection of cells with replicating virus or transfection of self 
replicating viral RNAs lead to the activation of type I IFN mRNA transcription. In 
addition, only full length RNA of TBEV was able to activate an IFNβ promoter driven 
reporter gene. Our results indicated that IFNα/β signalling is RNA replication 
dependent. Moreover, virus RNA replication is a central mechanism in the activation 
of type I IFN induction. 
Furthermore, we showed that the interferon regulatory factor 3 plays (IRF3) an 
important role in the control of viral replication. IRF3 deficient cells infected with 
TBEV exhibited a strong enhancement of virus replication. These cells did not 
activate IFNα/β. On the contrary, wild-type cells strongly induced IFN production, 
which lead to the suppression of virus replication, indicating that IRF3 is a main 
regulator in type I IFN signalling and essential to combat viral replication by inducing 
IFNα/β. 
Surprisingly, TBEV infection only lead to low IFNα/β activation and therefore we 
analysed if TBEV inhibits IFN expression. Finally, we identified TBEV as an inhibitor 
of the IFNα/β system. The virus interferes with components of the type I IFN 
signalling cascade at early stages by inhibiting IFN induction and on later periods in 
the establishment of an anti viral state by inhibition of STAT-1 phosphorylation.  
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Zusammenfassung 
 
Das Frühsommer-Meningoenzephalitis (FSME) Virus gehört zur Gattung der 
Flaviviren, Familie Flaviviridae und besteht aus einem einsträngigem RNA Genom 
mit positiver Polarität.  
Angeborene Immunität ist wichtig, um Virusstrukturen und Virusreplikation von RNA 
Viren zu erkennen. Säugetierzellen verfügen über pathogene Erkennungsrezeptoren 
(PRR) um Produkte der Virusreplikation zu erkennen und Signalkaskaden zu 
aktivieren, die zur Etablierung eines antiviralen Zustandes durch die Induktion von 
Typ I Interferonen (IFN) führen. 
In dieser Studie untersuchten wir die Interaktion des FSME Virus mit dem 
angeborenen Wirtsimmunsystem. Von besonderem Interesse war die Rolle von Typ I 
Interferonen in FSME Virus Infektionen in vitro und die Mechanismen die zur 
Interferon Aktivierung führen. 
Wir zeigten, dass die Infektion von Zellen mit replizierendem Virus oder die 
Transfektion von selbst-replizierender viraler RNA zu der Aktivierung von Typ I IFN 
mRNA Transkription führte. Zusätzlich war nur ″Ganzlängen″ RNA fähig ein 
Reportergen mit einem davor geschalteten IFNβ Promoter zu aktivieren. Unsere 
Ergebnisse bewiesen, dass IFNα/β Signalisierung von RNA Replikation abhängt. 
Weiters ist die virale RNA Replikation ein zentraler Mechanismus in der Aktivierung 
von Typ I IFN Induktion. 
Außerdem zeigten wir dass IRF3 (interferon regulatory factor 3) eine wichtige Rolle in 
der Kontrolle von viraler Replikation spielt. Mauszellen, die über kein IRF3 mehr 
verfügten und die mit TBEV infiziert wurden, wiesen eine stark erhöhte 
Virusreplikation auf. Diese Zellen aktivierten kein  IFNα/β. Im Gegensatz induzierten 
Wildtyp Zellen sehr stark die IFN Produktion, was zu einer Verminderung der 
Virusreplikation führte und zeigt, dass IRF3 ein Hauptregulator in der Typ I IFN 
Signalisierung ist. Der Transkriptionsfaktor ist wichtig, um Virusreplikation durch die 
Induktion von IFNα/β zu bekämpfen. 
Überaschenderweise führte die Infektion durch das FSME Virus nur zu geringer 
IFNα/β Aktivierung und aus diesem Grund testeten wir, ob es die Entstehung von IFN 
hemmt. Schließlich identifizierten wir das FSME Virus als einen Inhibitor des IFNα/β 
Systems. Das Virus interagiert mit Komponenten der Typ I IFN Signalkaskade in 
frühen Stadien durch die Inhibierung von IFN Induktion und in später Phase in der 
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Etablierung eines antiviralen Zustandes durch die Inhibierung von STAT-1 
Phosphorylierung. 
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1. Introduction 
 
1.1. Flaviviruses 
 
The genus Flavivirus consists of 53 virus species and among them 27 are mosquito-
borne, 12 are tick-borne and 14 are zoonotic agents with an unknown vector. It 
belongs to the family of Flaviviridae that are divided into three groups of closely 
related viruses: Flavivirus, Pestivirus and Hepacivirus. Viral classification is based on 
virion morphology, genome organization, vector associations and virus ecology 
(Fauquet and Fargette 2005).  
Flaviviruses are transmitted to vertebrates by blood sucking arthropods like 
mosquitoes and ticks. In very rare cases viruses can be transmitted vertically from 
vertebrate to vertebrate (Gaunt, Sall et al. 2001). Mosquito-borne flaviviruses include 
two major groups and can be distinguished by their clinical presentment in humans. 
On the one hand, Japanese encephalitis virus (JEV), West Nile virus (WNV), Murray 
Valley encephalitis virus (MVEV), and St. Louis encephalitis virus (SLEV) present the 
encephalitic flaviviruses and on the other hand, yellow fewer virus (YFV) and dengue 
virus (DENV) are viscerotropic and can cause hemorrhagic fever. The tick-borne 
Flaviviruses include tick-borne encephalitis virus (TBEV), Louping ill virus (LIV), 
Langat virus (LGTV), Powassan virus (POWV), Omsk hemorrhagic fever virus 
(OHFV), Kyasanur Forest disease virus (KFDV), Kadam virus (KADV), Royal Farm 
virus (RFV) and its subtype Karshi virus and Gadgets Gully virus (GGYV) (Charrel, 
Zaki et al. 2001). 
Flaviviruses have a genome that is single-stranded. The ~11-kb- long RNA molecule 
with positive-strand polarity carries a 5`-terminal Cap structure but no 3`-terminal 
poly(A) tail. It serves as the only viral mRNA that encodes all viral proteins in a single 
open reading frame (ORF). Virions are small round enveloped particles that consist 
of three structural proteins: capsid protein C, protein prM, which is a precursor to the 
small membrane protein M, and the large envelope protein E. The lipid envelope 
contains the two surface proteins, E and the membrane protein M. The capsid protein 
C and the viral genome can be found inside the viral envelope (Mandl 2005). The 
seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) have 
several functions in Virus replication. For example, they provide the RNA-dependent 
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RNA polymerase (NS5) and seem to have a role in modifying innate immune 
responses (Best, Morris et al. 2005). 
 
1.2. Flavivirus life cycle 
 
Flavivirus binding and uptake includes receptor-mediated endocytosis and the virus 
is internalized via clathrin-coated pits. The low pH of the endosomal pathway triggers 
fusion of the virion envelope with host cell membranes to release the virus 
nucleocapsid (Chu and Ng 2004). Moreover, the RNA genome, which serves as 
messenger RNA (mRNA) for translation and template during RNA replication, is 
released into the cytoplasm. The RNA is translated into a single polyprotein, which is 
processed by host and viral proteases. Whereas replication occurs on intracellular 
membranes, viral assembly takes place on the surface of the endoplasmic reticulum 
(ER). The replication starts with the synthesis of a genome-length minus strand RNA 
that later serves as a template of a complementary plus strand RNA (Lindenbach and 
Rice 1997). This synthesis, where minus strands serve as templates for the 
production of plus strands is called asymmetric replication (Chu and Westaway 
1985). Immature viral and subviral particles are transported through the trans-Golgi 
network (TGN) and cleaved by the host protease furin. Finally, they are released as 
mature and infectious particles by exocytosis (Fig. 1). 
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Fig. 1. Flavivirus life cycle 
Virions attach to the surface of the host cell and enter the cell by receptor-mediated endocytosis. 
Acidification of the endosomal vesicle leads to conformational change in the virion and to the fusion of 
viral and cell host membrane followed by particle disassembly. When the genome is released in the 
cytoplasma, the RNA is translated into a polyprotein and replication occurs on intracellular 
membranes. Virus assembly arises in the endoplasmic reticulum (ER) and non-infectious, immature 
particles are transported through the trans-Golgi network (TGN). They are cleaved by the host 
protease furin and released as mature, infectious particles by exocytosis. 
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1.3. Tick-borne encephalitis virus (TBEV) 
 
In 1931 TBEV was discovered in Europe and in 1937 the virus was isolated by 
Russian scientists. After Ixodes ticks were shown to be the vector of the disease, the 
virus was found to be spread in Eurasia (Lindquist and Vapalahti 2008). TBEV 
consists of the European (Eu), Far Eastern (FE) and Siberian subtype (Ecker, Allison 
et al. 1999). Whereas in Western Europe the principal vector is Ix ricinus, it is Ix 
persulcatus in eastern Eurasia (Mandl 2005). Cases of TBEV transmission to 
humans by the consumption of unpasteurized milk or by direct contact with infected 
sheep have also been documented (Komar 2003). 
TBEV can infect all groups of people, but in general the symptoms are more severe 
in older people than in children. The incubation period lasts between 7 to 14 days 
after a tick bite (Lesnicar, Poljak et al. 2003). The clinical symptoms differ slightly 
between the three subtypes. Febrile illness occurs in more than 70 % of the people 
infected with the European subtype. The beginning febrile period lasts 2 to 7 days 
without syndromes of meningoencephalitis, while thrombocytopenia and leokopenia 
are often observed. This first acute phase of infection is followed by a symptom-free 
interval. 30 % of the patients develop a second phase of disease. The fever returns 
and CNS symptoms, such as meningitis occur. Clinical syndromes like ataxia, 
cognitive dysfunction, concentration difficulties, confusion and paralysis emerge in 
infected patients (Lindquist and Vapalahti 2008). 
After the transmission to the host by the tick bite TBEV replicates in Langerhans cells 
and later in the macrophages, histiocytes and fibroblasts. When the virus enters the 
blood it multiplies in cells of the lymph nodes, in the spleen and in the liver. During 
the primary viremia, the virus is able to enter the central nervous system (CNS) via 
peripheral nerves, which leads to the second phase of viremia (Gelpi, Preusser et al. 
2005). The neuropathogenesis of TBEV includes neuroinvasiveness and 
neurovirulence. Neuroinvasiveness shows the capacity of the virus to enter the CNS, 
whereas neurovirulence is the ability of the virus to replicate and cause damage in 
the neurons of the CNS (Mandl 2005). 
There is no specific and established treatment for tick-borne encephalitis available, 
but the disease can be prevented by active immunization. Two vaccines based on 
nearly identical TBEV-Eu strains (strain Neudoerfl, FSME-IMUN by Baxter Vaccines, 
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Vienna Austria; strain K23, Encepur by Novartis, Basel, Switzerland) are approved 
and used successfully in Europe (Demicheli, Graves et al. 2000). 
 
1.4. Pattern recognition receptors 
 
Innate immunity and antiviral immune programs of mammalian cells play an 
important role and are necessary for the control of virus replication and spread during 
infection by RNA viruses. The cell is able to use pathogen recognition receptors 
(PRR) to detect products of viral replication in the form of pathogen-associated 
molecular patterns (PAMPs) (Kawai and Akira 2006). Viral recognition through PRRs 
leads to the activation of signalling pathways and to the induction of various latent 
transcription factors (Saito and Gale 2007). These transcription factors trigger the 
reprogramming of the cell’s gene expression and induce diverse genes to establish 
an antiviral state. Two latent and constitutively expressed transcription factors are 
interferon regulatory factor 3 (IRF3) and nuclear factor-κB (NF-κB). They are 
essential for the establishment of the antiviral state by the induction of type I 
interferons (IFNs) and through the induction of proinflammatory cytokines. 
Diverse classes of PRRs, Toll-like receptors (TLRs), the RIG-I-like helicase retinoic 
acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA-
5) have been demonstrated to take part in the activation of IRF3 and NF-κB 
signalling in response to Flaviviruses. 
 
1.4.1. Toll like receptors (TLRs) 
 
TLRs belong to the interleukin-1 receptor (IL-1R)/TLR superfamily, which also 
contains IL-1, IL-18 and IL-33 receptors. These receptors have a great importance in 
host innate immunity and are highly conserved (Akira, Uematsu et al. 2006).  
TLRs are either expressed on the cell surface or within endocytic vesicles (Saito and 
Gale 2007). Virus structures have been identified as target for TLR, including single-
stranded (ss) RNA that is recognized by TLR7 and TLR8; double-stranded (ds) RNA 
sensed by TLR3 and viral DNA detected by TLR9. Numbers of special viral structural 
proteins have been demonstrated to induce signal transduction through TLR2 and 
TLR4 (Akira, Uematsu et al. 2006). 
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Protein kinase R (PKR) has been shown to protect against viral infection and to 
sense intracellular dsRNA. Therefore, it represents the first antiviral PRR. 
Nevertheless, it has been observed that mice lacking the PKR gene could still induce 
an antiviral response after stimulation with poly I-C (pIC), which is a synthetic 
analogue of dsRNA. Consequently, TLR3 was discovered as a PRR to recognize 
dsRNA (Alexopoulou, Holt et al. 2001).  In general, TLR3 is located in the endosome 
and after detection of a viral pathogen the receptor recruits the TIR domain-
containing adaptor protein-inducing IFNβ (TRIF). Moreover, TRIF initiates a signalling 
complex that activates the IκB kinases (IKKs) TBK1 and IKK-ε, which further 
phosphorylate IRF3 (Au and Pitha 2001). Consequently, IRF3 forms homodimers 
and translocates to the nucleus, where it interacts with the CBP/p300 coactivator to 
activate the expression of IRF3 target genes. This leads to the establishment of an 
antiviral state to combat viruses and avoid viral replication (Yoneyama, Suhara et al. 
2002). The adaptor molecule TRIF also interacts with TRAF6 and RIP-1, which 
cause the induction of NFκB and the activation of proinflammatory cytokines 
(Cusson-Hermance, Khurana et al. 2005). 
TLR7 and TLR8 are both expressed in mice and humans and are highly homologous 
(Du, Poltorak et al. 2000). Synthetic ssRNA was shown to induce the stimulation of 
IFNα and proinflammatory cytokines from dendritic cells (DCs) and macrophages via 
human TLR8 and murine TLR7 (Heil, Hemmi et al. 2004).  
TLR9, which is located in the intracellular endosomal compartments, counteracts its 
PAMPs in endosomes like TLR3 (Ahmad-Nejad, Hacker et al. 2002). It has been 
known that TLR9 detects invading microorganisms by responding to bacterial DNA 
sequences that contain unmethylathed CpG dinucleotides (Hemmi, Takeuchi et al. 
2000). Large eukaryotic DNA viruses also contain a high number of these motifs. 
Therefore, infection of mice with members of the Herpesviridae, which are great DNA 
viruses, leads to the induction of type I interferons (IFNs) in plasmacytoid dendritic 
cells (pDC) via TLR9 (Krug, Luker et al. 2004). 
Although all TLRs activate NK-κB via MyD88- or TRIF-dependent pathways, type I 
IFN induction is regulated in a different way. While TLR4 and TLR3 induce IRF3 
through TRIF, TLR7 and TLR9 activate IRF7 through MyD88 (Ishii, Koyama et al. 
2008). 
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1.4.2. Rig like receptors (RLR) - Rig-I and MDA-5 
 
The retinoic acid-inducible gene I (RIG-I) like RNA helicase (RLH) family of PRRs 
includes RIG-I and melanoma differentiation-associated gene 5 (MDA-5). They are  
expressed in the cytosol and exhibit an alternative defence mechanism as an 
essential component of host innate immunity to RNA viruses (Kawai and Akira 2007). 
RIG-I is involved in the recognition of flaviviruses, orthomyxoviruses, 
paramyxoviruses and rhabdoviruses (Kato, Takeuchi et al. 2006). The receptor 
detects the uncapped 5´- triphosphate end of the ssRNA that is produced by these 
viruses (Hornung, Ellegast et al. 2006). Contrary, MDA-5 senses picornaviruses, but 
the exact RNA structure has not been identified yet.   
Further studies demonstrated that RIG-I is essential for recognizing HCV infection 
and especially binds to the non-translated regions (NTRs) within the virus genome 
(Saito, Hirai et al. 2007). Moreover, 5`ppp and dsRNA motifs were defined as RIG-I 
substrates (Hornung, Ellegast et al. 2006). 
RIG-I and MDA-5 contain two caspase-recruitment domains (CARDs) and a DExD/H-
box helicase domain. RLRs possess an ATPase activity that allows them to unwind 
dsRNA. When RIG-I recruits its CARD-containing adaptor IPS-I (also known as 
MAVS, VISA or Cardif), the adaptor relays the signal to the kinases TBK1 and IKKε, 
which phosphorylate IRF3 transcription factor (Thompson and Locarnini 2007). 
Diverse studies showed that RIG-I is necessary to activate expression of IFNβ in 
response to JEV infection (Kato, Takeuchi et al. 2006). RIG-I deficient mice showed 
a decrease in serum IFNα levels and an increased susceptibility to infection 
compared to wild-type mice, whereas MDA-5 knock out mice did not exhibit any 
phenotypic difference. Therefore, RIG-I plays an important role to initiate an antiviral 
response pathway to JEV. 
Contrary, RIG-I knock out mouse embryonic fibroblasts (MEFs) still induced IRF3 
target genes in response to DENV (Loo, Fornek et al. 2008). The same response 
occurred with MDA-5 null MEFs suggesting that the signalling pathway of DENV is 
more complicated and involves both RIG-I and MDA-5. 
RIG-I null cells still detected WNV infection, but the innate antiviral response was 
delayed (Fredericksen and Gale 2006). Consequently, RIG-I is essential to mediate 
antiviral response; nevertheless, various secondary pathways are also involved. 
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1.5. The interferon system 
 
Cytokines play a very important role in the host defence against viruses and the most 
prominent produced during viral infections are the interferons (IFNs). They contain 
three different classes: type I, II and III, according to the receptor they use (Randall 
and Goodbourn 2008). Type I IFNs consist of one to three IFNβ genes, multiple IFNα 
family members and other genes like IFNω, ε, τ, δ and κ. The IFNα and β genes can 
be produced by all nucleated cells in response to virus infection.  
Treatment of cells with type I IFNs leads to the upregulation and activation of several 
hundred genes, which promote the antiviral state. Some of the upregulated genes 
encode enzymes that are responsible to limit viral replication. For example, protein 
kinase R (PKR) and 2’5’-oligoadenylate synthetase (OAS) depend on viral co-factors 
like dsRNA and trigger huge changes in cellular function (e.g. translational arrest). 
Other IFN-inducible genes promote the upregulation of the major histompatibility 
complex (MHC) class I complex and the presentation of viral antigens to the adaptive 
immune response (class II MHC transactivator (CIITA) and transporter of antigen 
presenting 1/low molecular protein 2 (Tap1/LMP2)). Moreover, IFNα/β has 
immunomodulatory functions by triggering the maturation of dendritic cells (DCs), 
inducing natural killer (NK) cells and CD8+ T cells and promoting the synthesis of 
Interleukin-15 (IL-15), which is responsible for the division of memory CD8+ T cells 
(Randall and Goodbourn 2008). 
Type II IFNs contain only one member, IFNγ and they are predominantly made by T 
lymphocytes and NK cells. The last group, type III IFNs, consist of IFNλ1, λ2 and λ3, 
which are also induced in direct response to viral infection and use the same 
pathway like IFNα/β to detect viral infection (Onoguchi, Yoneyama et al. 2007). 
 
1.6. Activation of type I IFNs 
 
IFNα/β  production is tightly regulated at the transcriptional level. The IFNβ promoter 
has binding sites for several transcription factors, which cooperate for maximal 
induction. These are the IFN regulatory factor 3 and 7 (IRF3/7), NFκB and Ap-1 
(Honda and Taniguchi 2006). 
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IRF3 and IRF7 are expressed in many cell types. Either of these factors, when 
expressed ectopically, can enhance IFNα/β mRNA induction levels (Sato, Hata et al. 
1998; Sato, Tanaka et al. 1998). Transcriptional induction of IFNα/β genes during 
infection by different viruses, including vesicular stomatitis virus (VSV), herpes 
simplex virus (HSV), and encephalomyocarditis virus (EMCV), is commonly 
dependent on IRF family member (Sato, Suemori et al. 2000). However, IRF3 and 
IRF7 perform nonredundant and distinct roles from each other for the efficient 
induction of the IFNα/β gene, as well as for the diversity of the induction mechanisms 
within the IFNα gene family.  
Whereas IRF3 is constitutively expressed in almost all cells, IRF7 is only primary 
expressed in plasmacytoid dendritic cells. Type I IFNs have been proposed to 
produce feed backs onto cells by synthesising IRF7, which further induces 
transcription of the “primary” genes (IFNβ and murine IFNα) and activates 
transcription of the “secondary” genes (the remaining IFNα genes) (Sato, Hata et al. 
1998). IRF7 is capable to bind the IFNβ promoter and can enhance transcription 
significantly. 
IRF3 and IRF7 are activated through the phosphorylation of the C-terminus by the 
IKK related kinases IKKε and TBK1, which leads to dimerization. IRF3-dimers are 
translocated to the nucleus and bind to consensus binding sites in the promoter 
regions of type I IFN genes. (Panne, McWhirter et al. 2007). NF-κB is located in the 
cytoplasma and retained there by an inhibitor molecule called inhibitor of NF-κB 
(IκB). Viral infection induces the phosphorylation and subsequent proteaosomal 
degradation of IκB, which leads to the release and nuclear translocation of NFkB 
(Wullaert, Heyninck et al. 2006). 
IFNβ gene transcription requires also the binding of a c-jun/AFT-2 heterodimer to the 
promoter. IRF3, NFκB and c-jun/AFT-2 form a complex on the promoter, which is 
called enhanceasome. They support in a cooperative way the recruitment of CREB-
binding protein (CBP)/p300 that activates the congregation of the transcription 
machinery and RNA polymerase II (Merika and Thanos 2001). 
The production of type I IFNs in viral infections activates the transcription factor IRF7 
that seems to play a role in the induction process (Honda, Mizutani et al. 2004).  
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Fig. 2.  Type I IFN pathway 
Toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG-I) like RNA helicase (RLH) are 
expressed on and in a number of cells in host tissues that recognize diverse virus structures. They 
cooperate together to recognize viral infection by sensing viral proteins (TLR4), ssRNA (TLR7, TLR8), 
dsRNA (TLR3) and DNA (TLR9) viruses. ssRNA, for example, can be recognized by TLR3 on the cell 
surface or in the endosome in a MyD88 independent manner. After pathogen detection TLR3 recruits 
the adaptor molecule TRIF and initiates a signalling complex that activates the IκB kinases (IKKs) 
TBK1 and IKK-ε, which further phosphorylate IRF3. Phosphorylated IRF3 dimerizes and translocates 
to the nucleus where it supports the transcription of IFNβ and IFNα4 through the binding to their 
promoters. The kinases IKKα and IKKβ cause the induction of NFκB, which also leads to IRF3 
phosphorylation. RIG-I and MDA-5 are located in the cytosol and present an alternative way of viral 
defence. RIG-I, for instance, senses viral ssRNA and activates TBK1 and IKK-ε via IPS-I.  
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1.7. JAK-STAT pathway 
 
In general, all type I IFNs bind to a heterodimeric receptor, which is composed of 
IFNAR1 and IFNAR2. Whereas the cytoplasmic tail of IFNAR1 is associated with 
tyrosine kinase 2 (Tyk2), IFNAR2 is coupled to the tyrosine kinase JAK1 (Janus/just 
another kinase). IFNα/β binding leads to receptor oligomerization and activation of 
the receptor associated tyrosine kinases JAK1 and TYK2. The activated kinases 
phosphorylate IFN receptors and create recruitment sites for the cytoplasmic 
transcription factors signal transducers and activators of transcription 1 and 2 
(STAT1/2). STAT1/2 proteins bind to the tyrosine phosphorylated receptors through 
their SH2 domains and become phosphorylated by JAK1 and TYK2 on tyrosine 
residues. This leads to heterodimerization of STAT1 and STAT2 and to the 
subsequent nuclear translocation. STAT1-STAT2 heterodimer further associate with 
IRF9 to form a stable complex called interferon-stimulated gene factor (ISGF3). This 
complex binds to the IFN-stimulated response element (ISRE), which is a consensus 
sequence in the promoter of IFN stimulated genes (ISG) and enhances transcription 
of these genes. (Tang, Gao et al. 2007) (Reich and Liu 2006). 
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Fig. 3. JAK-STAT pathway 
Binding of type I IFN to their receptor leads to activation of the JAK-STAT pathway and subsequent 
activation of IFN target genes that play an important role in the antiviral immune response. 
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1.8. Viral evasion strategies 
 
Viruses of the family Flaviviridae are capable to use multiple mechanisms to escape 
the antiviral effects of IFN signalling in various ways. For instance, the NS proteins of 
some members of the Flaviviruses have been shown to act as IFN-antagonist, 
inhibiting the JAK-STAT pathway (Samuel and Diamond 2006). The main function of 
this pathway is to support the antiviral action of type I IFNs through ISG expression. 
Viral disruption of JAK-STAT signalling results in rapid viral replication, elevated viral 
loads in tissue and blood and enhanced transmission between hosts (Samuel and 
Diamond 2005). 
Pathogenic strains of DENV have been identified as very resistant viruses to the 
antiviral actions of IFNs. Viral NS2A, NS4A and NS4B have been suggested as 
possible IFN antagonists. Studies demonstrated that the mature NS4B protein in 
combination with NS4A blocks the nuclear import of STAT1 by inhibiting STAT 
phosphorylation (Munoz-Jordan, Sanchez-Burgos et al. 2003). Although the diverse 
virulence factors of the various DENV strains are still unknown, it might be obvious 
that they are able to interfere and suppress the JAK-STAT signalling cascade.  
Analyses of the NS5 protein of JEV identified the protein as IFN antagonist that is 
able to inhibit  the activation of Tyk2 and STAT1 (Lin, Chang et al. 2006). NS5 is the 
RNA polymerase of flaviviruses and essential for viral replication. Different studies 
showed that the NS5 protein of Langat virus, which is a member of the tick-borne 
flaviviruses, also functions as an IFN antagonist. It was demonstrated that the virus 
blocked IFN-induced phosphorylation of Tyk2 and JAK1 and could resist IFN’s 
antiviral effects after cells were already infected (Best, Morris et al. 2005). 
WNV infection and replication has been shown to be connected with an inhibition of 
IFN-induced JAK1 and Tyk2 phosphorylation. It has been reported that NS2A, 
NS2B3, NS4A and NS4B inhibit IFN signalling through interference of STAT 
activation (Liu, Wang et al. 2005).  
In general, chronic HCV infection is treated with IFN therapy, but in most cases HCV 
shows a low response rate to this therapy indicating that the virus is able to resist 
IFNs. Studies reported that HCV acts as an IFN-antagonist by inhibiting STAT1 
through elevated levels of protein phosphatase 2A, which hypomethylates and 
inactivates the transcription factor (Heim, Moradpour et al. 1999; Blindenbacher, 
Duong et al. 2003). Additionally, the HCV core protein activates expression of 
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suppressor of cytokine signalling (SOCS)-3 that function as a negative feedback loop 
on IFN signalling by inhibiting signal transduction events of the JAK-STAT pathway 
(Bode, Ludwig et al. 2003).  Different studies reported that HCV NS5A can inhibit 
IFNα indicating the protein as an IFN antagonist (Macdonald and Harris 2004).  
 
 
 
 
 
 
Fig. 4. Flaviviruses and HCV interfere with JAK-STAT signalling 
HCV inhibits STAT1-phosphorylation and induces SOCS-3 mRNA, which is responsible for the 
negative regulation of IFN-signalling. WNV and DENV NS4B protein partially blocks STAT1 activation. 
NS5 protein of LGTV interferes with JAK-STAT pathway by inhibiting STAT1 phosphorylation, 
whereas NS5 protein of JEV blocks STAT1 translocation to the nucleus. 
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2.  Aims 
 
 
Flavivirus infection leads to the activation of the host’s innate immune system and to 
the establishment of an antiviral state by the induction of cytokines and interferons 
(IFNs). In our study we investigated the induction and role of type I IFNs in TBEV 
infection. It has not been analysed yet, how type I IFN pathways are activated in 
TBEV infection and how the virus interacts with the innate immune system. 
Therefore, we studied the interaction of TBEV with the host’s interferon system. We 
were interested on the one hand which host cell factors contribute to the control of 
virus infection and on the other hand which parts of the viral replication cycle leads to 
the activation of host cell signalling pathways. 
It is known that numbers of Flaviviruses suppress type I IFN signalling to replicate 
unchallenged in the host cell. Therefore, we investigated if TBEV also interferes with 
the type I IFN pathway and inhibits IFN induction.  
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3. Materials and Methods 
 
3.1. Cells and viruses 
 
HEK 293T (293T cells): human kidney fibroblasts 
 
MEFs: mouse embryonic fibroblasts 
 
IRF3 -/- cells: mouse embryonic fibroblasts derived from IRF3 -/- mice 
 
RAW 264.7 (RAW cells): mouse macrophages 
 
L929 cells: mouse fibroblasts, established cell line, immortalised after 3T3 protocol 
(provided by Thomas Decker)  
 
Tick cells (IRE-18/19): cells of Ix ricinus 
 
BHK-21 cells: baby hamster kidney cells 
 
TBEV: Tick borne encephalitis virus, strain Neudoerfl of Western subtype TBEV 
 
VSV: Vesicular stomtatis virus, a member of the Rhabdovirus family, a (-)RNA 
stranded virus. Viral stocks were established from infected L929 murine fibroblasts 
 
3.2. Cell culture 
 
3.2.1. Cultivation of MEFs, L929, 293T cells 
 
Standard conditions for cultivation of cells are 37°C, 5 % CO2 and 95 % humidity. 
Medium has to be changed every 2-3 days. Whereas MEFs and 293T cells are split 
in the ratio 1:5, L929 have to be split 1:10. 
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Cells grow adherently in DMEM (GibCo Life Technologies), 10 % FCS and Pen/Strep 
(1x) in tissue culture treated dish. For passaging, medium is removed and cells are 
washed with 5 ml PBS. After PBS has been removed, cells are incubated in 1 ml 1x 
Trypsin/EDTA at 37°C for 1-2 min. Cells are resuspended and split in the appropriate 
ratio. 
 
3.2.2. Cultivation of RAW cells 
 
Standard conditions for cultivation of cells are 37°C, 5 % CO2 and 95 % humidity. 
Medium has to be changed every 2-3 days. Raw cells have to be split in the ratio 
1:10.  
Cells grow adherently in DMEM, 10 % FCS and Pen/Strep in tissue culture dish.  
For passaging, medium is removed and new one is added. Cells are scraped off the 
plat with a cell scraper, resuspended and split in the appropriate ratio. 
 
3.2.3. Cultivation of BHKs 
 
Standard conditions for cultivation of cells are 37°C, 5 % CO2 and 95 % humidity. 
Medium has to be changed every 3-4 days, when cells are split in the ratio 1:7.5. 
Cells grow adherently in medium (Minimal essential medium eagle, SIGMA  
#N1142), 5 % FCS, 1 % Glutamine, 0.5 % Neomycin in big cell culture bottles (175 
cm2). 
For passaging, medium is removed and cells are washed with 5 ml Trypsin. After 
discarding the Trypsin, another 5 ml are added. Trypsin is totally removed and cells 
are incubated at 37°C for 5 min. Cells are removed from the bottom by knocking 
against the cell culture bottle.  They are resuspended with fresh medium and split in 
the appropriate ratio. 
 
3.2.4. Cultivation of Tick cells 
 
Standard conditions for cultivation of cells are 28°C, without CO2 or humidity in 
closed tubes (3 cm2).  Medium has to be changed every week and cells are split in 
the ratio 1:2. 
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For passaging, medium is discarded and fresh one added. Cells are removed by 
pipetting the medium up and down for 10-20 times. 
 
Medium for Ticks 
Total amount of medium 50ml 75ml 100ml 
L15  17ml 25.5ml 34ml 
HBSS 18ml 27.5ml 36ml 
Tryptose-PO4-broth 2.5ml 3.75ml 5ml 
Lactalbumin hydrolysate 10% 1.25ml 1.8ml 2.5ml 
FCS 10ml 15ml 20ml 
L-Gln 200mM 0.5ml 0.75ml 1.0ml 
PSA 0.5ml 0.75ml 1.0ml 
Added for infection    
1M Hepes 1ml   
1N NaOH 300μl   
 
 
3.2.5. Freezing and thawing cells 
 
Freezing 
- Cells are washed in a 10 cm confluent tissue culture dish with 5 ml PBS 
- Remove PBS and add 1 ml Trypsin/EDTA 
- Incubated at 37°C 1-2 min 
- Resuspend cells in 9 ml medium and transfer to a Falcon tube 
- Centrifuge for 5 min, at 1000 rpm at room temperature (RT) 
- Discard supernatant and resuspend the pellet in 3 ml 90 % FCS / 10 % DMSO 
(Sigma) 
- Transfer 1 ml aliquots into cryotubes and put them on ice for 10 min 
- Put cryotubes at -80°C  
 
Thawing 
- Let cells thaw at RT and transfer them into Falcon tube 
- Centrifuge for 5 min at 1000 rpm, RT 
- Remove supernatant, resuspend cells in 1 ml medium and transfer them into a 
10 cm culture dish with 9 ml medium 
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3.2.6. Coating of 24-well plates (293T cells) 
 
Reagents 
Borate Buffer         Dissolve 0.15 M sodium tetraborate decahydrate    
(Na2B4O7*10H2O) in ddH2O (pH 8.3) 
Filter sterilize 
 
 
293T cells are not very adherently and therefore 24 well plates have to be coated 
with Poly-D-Lysin before seeding cells.  
 
- Dilute Poly-D-Lysin (1mg/ml) in Borate Buffer 1:4 
- Add 200 µl per well 
- Incubate 2-24 hours RT 
- Remove Poly-D-Lysin and wash 2-3x with PBS 
- Seed 293T cells 
 
3.2.7. Cell seeding (transfection, elctroporation, immunofluorescence and 
western blotting) 
 
  24 well 6 well 6cm plate 
MEFs 1 x 105 2,5 x 105 5 x 105 
293T 1 x 105 2,5 x 105 5 x 105 
L929 5 x 104 1 x 105 2 x 105 
RAW 5 x 104 1 x 105 2 x 105 
 
 
3.2.8. Transfection of cells 
 
3.2.8.1. Transfection with Transmessenger Transfection Reagent (protocol Qiagen) 
- Seed cells 1 day before transfection in 24 well plate  
- Dilute 2 µl Enhancer-R in Buffer EC-R. Add 1 µg RNA/DNA and mix by 
vortexing for 10 seconds (s). The final volume should be 100 µl. 
- Incubate at room temperature for 5 min, and then spin down the mixture. 
- Add 4 µl Transmessenger Transfection Reagent. Mix by vortexing. 
- Incubate 10 min RT 
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- While complex formation takes place, gently aspirate the growth medium from 
the plate and carefully wash cells 1-2 times with PBS using 1.5-2 times the 
volume of medium used for seeding 
- Add 100 µl medium without serum and antibiotics to the transfection complex. 
Mix by pipetting, then immediately drop it onto the cells. 
- Incubate cells for 3 h 37°C. 
- Remove complexes and add fresh medium containing 1 % FCS and P/S 
 
3.2.8.2. Transfection with Lipofectin (protocol Invitrogen) 
- Seed cells 1 day before transfection in 24 well plate 
- Dilute 1 µg RNA/DNA with DMEM (without FCS and antibiotics) to a total 
volume of 50 µl 
- Dilute 2.5 µl Lipofectin with 48 µl DMEM (total volume 50 µl) 
- Incubate 30 min RT 
- Mix DNA with Lipofectin and incubate for 5 min RT 
- Wash cells with PBS 
- Drop DNA-Lipofectin mix (100 µl) on cells and incubate for 5 hours 
- Remove complexes and add fresh medium containing 1 % FCS and P/S 
 
3.2.8.3. Transfection with LipofectaminTM 2000 (protocol Invitrogen) 
- Seed cells 1 day before transfection in 24 well plate 
- Next day: dilute 0,8 µg RNA/DNA in 50 µl Opti-MEM (Gibco) without serum, 
mix gently 
- Mix Lipofectamin gently before use, then dilute 2 µl in 50 µl of Opti-MEM 
- Incubate for 5 min at room temperature 
- Combine diluted DNA with diluted Lipofectamin 
- Incubate for 20 min 
- While complex formation takes place, gently aspirate the growth medium from 
the plate and carefully wash cells 1 time with PBS  
- Add 100 µl medium without serum and antibiotics 
- Add the 100 µl of complexes to each well containing cells and medium. Mix 
gently. 
- Incubate cells at 37°C for 24 h. 
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- Remove complexes and add fresh medium containing 1 % FCS and P/S after 
4-6 h 
 
3.2.8.4. Electroporation: 
- Cells were incubated with 1xTrypsin/EDTA and resuspend in 5 ml medium 
(DMEM) with 10 % FCS 
- Count cells and use 2.5x106 for electroporation 
- Centrifuge cells 5 min 1200 rpm 
- Wash 2x with cold PBS (5 min 1200 rpm) 
- Add 0.8 ml PBS, dissolve pellet 
- Transfer cells in a cuvette and add 5 µg RNA 
- Electroporate with 2 pulses: 1.8kV; 200Ω; 25µF 
- Add 5 ml medium 
- Count cells 
- Seed 2-5x105 cells per well (for taking different time points) 
- Use 2x105 cells for cytoplasmic RNA isolation (see protocol page 44) 
 
3.2.9. Infection of cells 
 
Infection Medium: 
   DMEM 
1%FCS 
15mM Hepes pH 7.4 
 
- Wash cells 1 time with infection medium 
- Infect cells with MOI 1 (TBEV: 1x108 FFU/200 µl virus → 0.2 µl virus for 1x105 
cells) and incubate for 3-4 hours 
- Remove medium and wash cells 1x with 2 ml infection medium  
- Add fresh infection medium (0.5 ml for 6 cm plate) 
 
3.2.10. Immunofluorescence  
 
- Put sterile small glass plates into 24 well plates and seed cells  
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Fixating of cells 
- Remove medium and add 500 µl PBS (ice cold) 
- Remove PBS and add 500 µl ice cold Methanol/Acetone (1:1)  
- Put plate for 10 min at -20°C 
- Remove MeOH/Ac and let plates dry on RT 
Staining of cells 
- Cover small plates with a drop of 1x PBS 
- Remove the drop and add 25 µl of the 1st antibody dilution: Kpm-2 (rabbit α 
prM/E NS-1) diluted 1:50 in 1x PBS 
- Incubate 1 h/37°C in a wet chamber 
- Wash 2 times with PBS, dry with ventilator 
- Cover small plates with a drop PBS 
- Remove the drop and add 25 µl of the 2nd antibody dilution: FITC (goat α 
rabbit IgG Fitc) diluted 1:25 in naphthalene black 
- Incubate 1 h/37°C 
- Wash 2 times with 1x PBS, dry with ventilator 
- Fix small plates with mounting medium (Depex, Serva electrophoresis) on 
microscope slides 
- Observe under the microscope 
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3.3. In vitro transcription  
 
To obtain a linear DNA fragment for the in vitro transcription, the C17 and dBSSH 
plasmids (derivates of pTNd/c, an infectious cDNA clone of TBEV strain Neudoerfl 
(GenBank accession number U27495)) (Mandl, Ecker et al. 1997) were cut with 
NheI. Furthermore, the ends were blunted with Klenow. After the cleanup with Qiaex 
II System, the DNA was loaded on an agarose gel (Fig. 5). 
 
3.3.1. NheI digest and Klenow fill up 
 
6 µg DNA Mega Prep  
5 µl Tango Buffer 
4 µl NheI 
X µl ddH2O 
50 µl total 
 
→ 1 h 15 min 37°C 
 
3 µl CTP 
3 µl TTP 
10 µl Klenow Buffer 
33 µl H2O 
1 µl Klenow fragment 
50 µl NheI digest 
100 µl total 
 
→ 15 min 25°C 
 
3.3.2. Cleanup of DNA with Qiaex II System (according to Qiagen)  
 
- Add 3 volumes of Buffer QX1 to 1 volume of sample 
- Check that the color is yellow 
- Resuspend QIAEX II by vortexing 30 s 
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- Add 10 µl of QIAEX per 5 µg of DNA and mix. Incubate at RT 10 min, mix 
every 2 min  
- Centrifuge sample for 30 s and remove supernatant 
- Wash the pellet twice with 500 µl Buffer PE 
- Air dry pellet for 10-15 min until it becomes white 
- Elute the DNA in 32 µl H2O 
 
3.3.3. Cleanup of DNA with Phenol-Chloroform 
 
- Add 100 µl nuclease free (NF) water to 100 µl sample and 200 µl Phenol 
(1xVol), vortex sample 
- Centrifuge 1-2 min full speed 
- Put the water phase into new Eppendorf tube  
- Add 200 µl Chloroform-Isoamylalcohol (24:1), vortex  
- Centrifuge 1 min 14000 rpm and put water phase into new tube 
- Add NF water to the sample to a total volume of 200 µl 
- Add 1/10 (20 µl) NaAc (3 M, pH 5-6) 
- Add 3xVol 96 % EtOH (-20°C) and vortex 
- Centrifuge 15 min 13200 rpm 
- Discard supernatant (SN) and wash pellet in 1 ml 70 % EtOH 
- Centrifuge 15 min 13200 rpm 
- Discard SN 
- Dissolve pellet in 32 µl RNase free (RF) water 
 
 
 
 
Fig. 5. C17 plasmid DNA (1) and dBSSH plasmid DNA (3) were digested with NheI (2, 4).  
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3.3.4. In vitro transcription with T7 megascript (Ambion) 
 
After the DNA was in vitro transcribed into RNA a DNase digestion was performed. 
Moreover, the RNA was cleaned up with RNeasy Mini Kit or phenol chloroform 
extraction and then RNA quality was checked on a RNA gel (Fig. 6). The exact 
amount of RNA was determined via photometric measurement. 
 
2 µl ATP 
2 µl CTP 
2 µl UTP 
0.4 µl GTP 
0.5 µl Cap 
2 µl buffer 
3 µl ddH2O 
12 µl total 
 
→ 3-4 h 37°C 
 
DNase digest 
20 µl RNA 
1 µl DNase 
 
→ 15 min 37°C 
 
3.3.5. Cleanup of the RNA with RNeasy Mini Kit (Qiagen) 
 
- Adjust the sample to a volume of 100 µl with RF water 
- Add 350 µl Buffer RLT and mix well 
- Add 250 µl EtOH (96-100 %) and mix well by pipetting. Do not centrifuge. 
- Transfer sample to a column and centrifuge for 15 s at 10000 rpm 
- Add 500 µl Buffer RPE to the column, centrifuge 15 s at 10000 rpm 
- Add 500 µl Buffer RPE, centrifuge 2 min 10000 rpm 
- Place column in a new 2 ml collection tube, centrifuge 1 min 13000 rpm 
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- Place column in new 1.5 ml collection tube. Add 60 µl RF water and centrifuge 
1 min 10000 rpm to elute RNA 
 
3.3.6. RNA gel  
 
Reagents 
10x MOPS         0.2 M MOPS  
50 mM NaOAc  
10 mM EDTA  
+ ddH2O → 1l (pH 7.0) 
 
RNA-Gel             0.5 g GTG-Agarose 
37 ml Ambion-H2O (nuclease free water, Ambion) 
5 ml 10x MOPS 
Boil up, cool down → add 8ml formaldehyde (HCHO)  
→ pour the gel 
 
The quality of the RNA can be checked on a formaldehyde gel (RNA gel). Firstly the 
gel runs at 35 mA for 5 min and then at 55 mA for 55 min. 
 
5 µl digest 
5 µl ddH2O 
10 µl RNA loading buffer (LB) 
1 µl Radiant Red 
16 µl total 
 
2 µl marker 
3 µl ddH2O 
5 µl RNA LB 
0.5 µl Radiant Red 
10.5 µl total 
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3.3.7. Photometric measurement 
 
The RNA is diluted in 10 mM Tris Cl (pH 7.5) and concentration is determined by 
measuring ultraviolet absorbance at 260 nm and 280 nm with the spectrophotometer. 
The received RSLT value has to be multiplied with the factor of dilution and the 
obtained result is the amount of RNA in µg/ml. 
 
 
 
 
Fig. 6. C17 and dBSSH DNA was in vitro transcribed into RNA and a DNase digestion was performed. 
Moreover, the RNA was cleaned up with RNeasy Mini Kit and checked on a RNA gel. 
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3.4. Protein analysis 
 
3.4.1. Antibodies 
 
- STAT 1 (Cell Signaling Technology) 
- Phospho-STAT1 (Tyr701) Antibody (Cell Signaling Technology) 
- ERK1 and ERK2 (pan ERK) (Cell Signaling Technology) 
- Amersham ECL Anti-Mouse IgG, Horseradish Peroxidase-Linked Species-
Specific Whole Antibody (from sheep) (GE Healthcare) 
 
3.4.2. Cell extracts 
 
Whole cell extracts using a detergent buffer 
 
Reagents 
Frackelton buffer (FB)                        10 mM Tris base              
50 mM NaCl                        
30 mM Na-pyrophosphat     
50 mM NaF                          
1 % Triton X-100           
pH 7-7.5; store at 4°C 
Add just before use: 
1 mM PMSF 
1 mM DTT 
10x protease inhibitors (Roche) 
(dissolved in FB) 
10x phosphatase inhibitors (Roche) 
(dissolved in FB) 
 
SDS sample buffer (24ml)                  6 ml TRIS 0.5 M pH 6.8 
2 ml 2-β-mercaptoethanol 
2.5 ml glycerol 
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4 ml 10 % SDS 
9.5 ml H2O 
0.5 % (w/v) bromphenol blue 
Store at -20°C 
 
The whole process has to be performed on ice and in the presence of protease and 
phosphatase inhibitors to prevent dephosphorylation by phosphatases. 
 
- Remove medium from the cell 
- Transfer plate on ice 
- Wash cells with cold PBS 
- Remove PBS well 
- Add 80 µl ice-cold Frackelton Buffer to cells on a 6 cm dish 
- Scrape cells with a cell scraper and transfer them to a micro centrifuge tube 
- Centrifuge 5 min at 14000 rpm at 4°C 
- Transfer supernatant into a new micro centrifuge tube  
- Add 40 µl SDS-sample buffer  
- Boil for 10 min at 95°C 
- Store samples at -20°C or use directly 
 
3.4.3. SDS polyacryamide gel electrophoresis 
 
Reagents 
10x running buffer for SDS PAGE      0.25 M Tris 
1.92 M glycin 
1 % (w/v) SDS 
 
10 % (w/v) SDS 
Dissolve 10 g sodiumdodecylsulfate in H2O and add to 100 ml 
 
4x separation gel buffer                     1.5 M Tris-HCl, pH 8.8 
 
4x stacking gel buffer                         0.5 M Tris-HCl, pH 6.8 
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  Separation Gel (10%) Stacking Gel (4%) 
Acryl amid 40 % 1 ml 0.2 ml 
Tris 1 ml (pH 8.8) 0.6 ml (pH 6.8) 
H2O 2 ml 1.3 ml 
SDS (10%) 40 µl 20 µl 
TEMED 12 µl 6 µl 
APS (20%) 12 µl 6 µ 
 
 
- Assemble the glass plates according to the manufacturer’s instructions 
- Prepare separation gel and pour it  
- Cover separation gel with 70 % EtOH and wait until it is polymerized 
- Remove EtOH and wash with dH2O 
- Pour the stacking Gel and insert the comb 
- Wait until gel is polymerized 
- Put gel in the electrophoresis apparatus and add SDS running buffer  
- Load 15 µl of the samples and 7 µl of a molecular weight marker (PageRulerTM 
Prestained Protein Ladder, Fermentas) 
- Run the gel first 80 Volt until proteins enter the separation gel, then switch to 
110 V 
 
3.4.4. Western blotting 
 
Reagents 
Anode buffer I         0.3 M Tris  
                                          20 % Methanol 
                                          pH 10.4 
 
Anode buffer II       2.5 mM Tris  
                                         20 % Methanol 
                                         pH 10.4 
 
Cathode buffer      0.04 M amino-caprionic acid  
                                        20 % Methanol 
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                                        0.01 % SDS 
 
     Ponceau S           0.2 % (w/v) Ponceau S 
                                  3 % (w/v) trichloroacetic acid 
 
- Put PVDF membrane in Methanol, nitrocellulose membrane in dH2O, then 
shortly in Anode II Buffer 
- Gel is inverted on the plate 
- Put membrane on gel 
- Put  3 Whatmann papers into Anode II buffer and then on gel 
- Soak 6 Whatmann papers in Anode I buffer and add them 
- Turn around gel and papers 
- Add 6 papers soaked in Cathode buffer 
- The blotting is performed in a semy dry blotting apparatus at 0.8 mA per cm2 
(= 60 mA/minigel), constant voltage of 20 V for 120 min 
- After the blotting is completed the membrane is rinsed with H2O and stained 
with Ponceau S to test the quality of the protein transfer. The stain is removed 
by washing with water for 5 min. 
 
3.4.5. Immunostaining  
 
- Block the membrane with 5 % milk in TBST or 2 % BSA in TBST for 60 min 
- Rinse the membrane with TBST and wash 3 times for 10 min with the buffer 
- Incubate the membrane with the antibody solution overnight at 4°C on a 
shaker 
- Wash 3x with TBST for 10  min 
- Add secondary antibody- anti mouse or anti rabbit coupled to HRP 1:5000 in 
TBST for 30 min 
- Wash 3x with TBST 10 min 
- Detection with ECL-system (purchased from Pierce) in the dark room 
- Cover the membrane with 1:1 mixture of Super Signal ECL – detection 
solution 1 and 2 for 1-2 min 
- Expose to a Fuji X-ray medical film 
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The following antibody solutions have been used 
 
Anti-pY701, 1:2000, 1 % BSA, 0.05 % NaN3 in TBST 
Anti-S1-C, 1:2000, 1 % BSA, 0.05 % NaN3 in TBST 
Anti-panERK, 1:2000, 1 % BSA, 0.05 % NaN3 in TBST 
 
3.4.6. Stripping of membranes 
 
Reagents 
Stripping buffer           200 mM Glycin 
150 mM NaCl 
0.5 % (v/v) Tween 20 
pH 2.5 
autoclave 
 
- Rinse the membrane shortly in water 
- Incubate for 10 min in stripping buffer at RT 
- Rinse membrane again with water 
- Repeat the immunostaining procedure or dry the membrane between 
Whatmann papers 
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3.5. Real-time PCR 
 
3.5.1. Oligonucleotides   
 
Real-time PCR Primers were purchased by VBC-genomics.  
TaqMan (Tqm) probes were labelled with the reporter dye 6-carboxy-fluorescein 
(FAM) on the 5’ end and the quencher dye 6-carboxy-tetramethyl-rhodamine 
(TAMRA) on the 3’ end.  
 
gene FSME-NS5  
forward FSME NS5-1 5’-GAAGCGGAGGCTGAACAACT-3’ 
reverse FSME NS5-2 5’-TTGTCACGTTCCGTCTCCAG-3’ 
probe FSME-NS5-Tqm 5’-TGTGTACAGGCGCACCGGCA-3’ 
   
gene Ubiquitin conjugating enzyme 2d2 (Ube2d2) 
forward Ube2d2-f 5’-AGGTCCTGTTGGAGATGATATGTT-3’ 
reverse Ube2d2-r 5’-TTGGGAAATGAATTGTCAAGAAA-3’ 
probe Ube2d2 FAM 5’-CCAAATGACAGCCCCTATCAGGGTGG-3’ 
   
gene Cxcl10 (IP-10)  
forward IP-10(44)-f  5’-GTCTGAGTGGGACTCAAGGGATC-3’ 
reverse IP-10(120)-r  5’-CACTGGCCCGTCATCGATAT-3’ 
probe IP-10(88)FAM  5’-CTCTCGCAAGGACGGTCCGCTG-3’ 
   
gene Interferon alpha 4  
forward IFNa4-f 5’-CCTGTGTGATGCAGGAACC-3’ 
reverse IFNa4-r 5’-TCACCTCCCAGGCACTGA-3’ 
probe IFNa4 FAM  5’-AGACTCCCCTGCTGGCTGTGAGGACA-3’ 
   
gene pan Interferon alpha  
forward panIFNa(453)-f 18ATdeg 5’-CCACAGGATCACTGTGT(AT)CCTGAGA-3’
reverse panIFNa(513)-r 5’-CTGATCACCTCCCAGGCACAG-3’ 
probe panIFNa(479) FAM LNA 5’-AG+AA+GAA+A+C+AC+AG+CC-3’  
   
gene GADPH  
forward GAPDH-f 5'-TGCACCACCAACTGCTTAGC-3' 
reverse GAPDH-r 5'-GGCATGGACTGTGGTCATGAG-3' 
   
gene IFNß  
forward IFNß-f 5'-TCAGAATGAGTGGTGGTTGC-3' 
reverse IFN-ß-r 5'-GACCTTTCAAATGCAGTAGATTCA-3' 
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3.5.2. RNA isolation 
 
Reagents 
Na2PO4-gel        100 ml 1x RNA buffer (0.01 M Na2HPO4, 0.01 M NaH2PO4) 
                           2 agarose tablets 
                           5 µl ethidium bromide 
                           Run gel for 1h 50 volt 
 
RLN buffer         50 mM TrisHCl (1 M) 5 ml 
           (100 ml)             140 mM NaCl (5 M) 2.8 ml 
                          1.5 mM MgCl2 (1 M) 250 µl 
                                       0.5 % (v/v) Igepal 500 µl 
                                     91.55 ml H2O 
 
1M DTT             3.1 g dithiothreitol in 20 ml of 0.01 M sodium acetate (pH 5.2) 
                     Filter sterile and store at -20°C 
 
3.5.2.1. Purification of total RNA from animal cells using spin technology (according 
to Quiagen) 
- Wash the cells with 1x PBS 
- Add 350 µl Buffer RLT and scrape the cells off the plate 
- Add 1 volume of 70 % EtOH and mix well by pipetting 
- Transfer the sample to an RNeasy spin column and centrifuge for 15 s 10000 
rpm 
DNase digestion:  
1. add 350 µl Buffer RW1, centrifuge 15 s 100000 rpm 
2. add 10 µl DNase stock solution (Quiagen) to 70 µl Buffer RDD, mix 
gently 
3. add the mix (80 µl) to the spin column membrane and place on the 
bench top for 15 min 
- add 350 µl Buffer RW1, centrifuge 15 s 10000 rpm 
- Add 500 µl Buffer RPE, centrifuge 15 s 10000 rpm 
- Add 500 µl Buffer RPE, centrifuge 2 min 10000 rpm 
- place column in a new collection tube, centrifuge 1 min full speed 
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- Place column in a new centrifuge tube. Add 40 µl RNase-free water and 
centrifuge 1 min 10000 rpm 
- Add another 40 µl RNase-free water and centrifuge 1 min 10000 rpm 
 
3.5.2.2. Isolation of cytoplasmic RNA (according to Quiagen) 
-    Prepare Buffer RLN (always add 1 mM DTT fresh) 
- Add 175 µl cold RLN and resuspend cells 
- Incubate on ice 5 min 
- Centrifuge at 4°C at 1200 rpm 5 min 
- Transfer supernatant into a new tube 
- Add 600 µl Buffer RLT  
- Add 430 µl EtOH, mix by pipetting, do not centrifuge 
- Apply 700 µl to a column, centrifuge 15 s 10000 rpm. Discard the flow-
through. Repeat with remaining sample 
- Add 700 µl Buffer RW1, centrifuge 15 s 10000rpm 
- Transfer column into new tube. Add 500 µl Buffer RPE, centrifuge 15 s           
10000 rpm 
- Add another 500 µl RPE, centrifuge 2 min 10000 rpm 
- Place column in a new tube, centrifuge 1 min full speed 
- Transfer column to a new 1.5 collection tube. Add 60 µl RF water directly on 
membrane, centrifuge 1 min 10000 rpm to elute. 
 
The quality of the RNA is checked with a Na2PO4-gel and the concentration is 
determined in the spectrophotometer by measuring ultraviolet absorbance at 260 nm 
and 280 nm with the spectrophotometer. The received RSLT value has to be 
multiplied with the dilution factor and the result indicates the concentration of the 
RNA in µg/ml. 
 
3.5.3. cDNA synthesis  
 
RNA samples are reverse transcribed in cDNA for real-time PCR according to Biorad 
iScriptTM cDNA synthesis users manual. 
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10 µl RNA (~1 µg) 
5 µl H2O 
4 µl 5x iScript Reaction Mix 
1 µl Reverse Transcriptase 
20 µl total 
 
PCR reaction: 
5 min      25°C 
30 min    42°C 
5 min      85°C 
Hold at     4°C 
 
3.5.4. Real-time PCR 
 
The real-time experiments are performed on the 7300 Real-Time PCR System 
(Applied Biosystems). 
 
3.5.4.1. Calculation of the molecular weight of TBEV RNA copies 
Program used: http://www.basic.northwestern.edu/index.html 
Wt TBEV: 3.46 x 1012 µg/mol……………..................a 
Avogadro’s number: 6.06 x 1023/mol RNA…………..b 
b/a = 1.66 x 1011 molecules/µg RNA 
 
3.5.4.2. Determination of RNA copies of TBEV 
Viral RNA (C17) dilutions from 102 to 107 are used as a standard and for quantitation 
the standard curve method is used: 
http://www.biotech.uiuc.edu/centers/Keck/Functional_genomics/taqman/Guide%20to
%20relative%20quantitation.pdf 
 
FSME-NS5 
 
Master Mix 
12.5 µl TaqMan® Universal PCR Master Mix   
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            0.4 µl primer 1 (P1) (100pmol/µl) 
 0.4 µl primer 2 (P2) (100pmol/µl) 
 0.1 µl TaqMan probe (100pmol/µl) 
 6.6 µl H2O 
 5 µl template (cDNA) 
 25 µl total volume 
 
3.5.4.3. Determination of gene inducibility 
 
Pan alpha 4, pan IFN alpha, IP-10 
 
Ubiquitin-conjugating enzyme E2D 2 (Ube2d2), a housekeeping gene, is chosen as 
an endogenous control for normalization of the RNA load  
 
Master Mix  
12.5 µl TaqMan® Universal PCR Master Mix   
0.75 µl P1 (10 pmol/µl) 
0.75 µl P2 (10 pmol/µl) 
0.25 µl TaqMan probe (10 pmol/µl) 
           6 µl H2O 
5 µl template (cDNA diluted 1:5) 
25 µl total volume 
 
IFNβ 
 
Glyceraldehyde-3-phosphate dehydrogenase (GADPH), a housekeeping gene, is 
chosen as an endogenous control for normalization of the RNA load. 
 
Master Mix (IFNβ) 
12.5 µl TaqMan® Universal PCR Master Mix   
0.5 µl P1 (100 pmol/µl) 
0.5 µl P2 (100 pmol/µl) 
1 µl probe (syber green 1:1000) 
0.375 FITC 
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           0.125 µl H2O 
10 µl template (cDNA diluted 1:5) 
25 µl total volume 
 
Master Mix (GADPH) 
12.5 µl TaqMan® Universal PCR Master Mix   
0.2 µl P1 (100 pmol/µl) 
0.2 µl P2 (100 pmol/µl) 
1 µl probe (syber green 1:1000) 
0.375 FITC 
           5.725 µl H2O 
5 µl template  
25 µl total volume 
 
For quantitation of gene expression normalized to an endogenous control the 
standard curve method is used: 
http://www.biotech.uiuc.edu/centers/Keck/Functional_genomics/taqman/Guide%20to
%20relative%20quantitation.pdf 
 
3.5.4.4. Standard curve equation: 
The resulting CT values (PCR cycles to reach a fixed threshold of DNA synthesis) of 
the diluted cDNA sample are plotted against the log input copy number: CT values = 
m* (log input copy number) + b 
The copy numbers of the samples are normalized for diverse amounts of cDNA 
added to the reaction, to copy numbers of the endogenous Ube 2d2/GADPH control. 
Finally, the normalized amount of target is divided by the target quantity of the 
calibrator, which is the unstimulated control and has the lowest expression level of 
the target. Therefore, the stimulated samples are expressed as n-fold increase 
(inducibility) to the calibrator.  
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3.6. Luciferase assay 
 
Plasmids 
- Renilla  pRL-SV40 Vector (Promega) 
- Renilla pRL-null Vector (Promega) 
- Renilla pRL-CMV Vector (Promega) 
- p125-Luc: Firefly luciferase plasmid under the control of an IFNβ promoter 
(provided by Takashi Fujita) 
 
1st day:  
Seeding of cells (293T) 
1x105 cells per well are seeded in coated 24 well plates. 
 
2nd day:  
Transfection of plasmids (Renilla + firefly) with Lipofectin  
A transfection of 0.1 µg Renilla as control plasmid and cotransfection of 0.1 µg 
Renilla and 0.9 µg firefly are performed. 
 
3rd day:  
Transfection of RNA (1µg/ml) with Transmessenger Reagent and infection of cells 
 
4th day: 
Preparation of cells for luciferase assay  
- Wash cells with PBS 1 time 
- Add 200 µl Trypsin/EDTA for 1-2 min at 37°C 
- Add 700 µl Medium (EMEM) 
- Resuspend the cells the plate and put them into a microcentrifuge tube 
- Centrifuge 2-3 min with a table top centrifuge 
- Remove supernatant 
- Add 180 µl RLN+DTT  
- Put  tubes 5 min on ice 
- Centrifuge 5 min 1200 rpm 4°C 
- Put the supernatant into a new tube 
- Store samples at -80°C or use (measure luciferase) them directly  
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Measurement of relative light units (RLUs) 
- Take 75 µl of the sample for luciferase assay and add to 48 well plate  
- Add 75 µl firefly substrate (Dual-GloTM Luciferase reagent, Promega) 
- Measure the firefly luminescence with the luminometer (Victor Light 
Luminometer, Perkin Elmer) 
- Add 75 µl Renilla substrate (Dual-GloTM Stop & Glo Luciferase reagent, 
Promega) 
- Measure the Renilla luminescence with the luminometer  
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3.7. Mega Prep  
 
3.7.1. Production of electro competent HB101 E.coli cells 
 
- Prepare 2x 5 ml over night culture of HB101 (37°C, 280 rpm) 
- Next day: dilute the culture 1:100 and put it on the shaker until it reaches 
OD600=0.5-1  
- Put it on ice 15-30 min 
- Centrifuge 15 min 5000 rpm (Rotor F16, Sorvall) 
- Discard the supernatant and resuspend pellet in 6x 165 ml H2Odd, 4°C 
- Centrifuge 15 min 5000 rpm and discard supernatant  
- Resuspend pellet in 3x 165 ml H2Odd, 4°C 
- Centrifuge 15 min 5000 rpm and discard supernatant  
- Resuspend pellet in 2 ml 10 % glycerin, 4°C 
- Make 50 µl aliquots on dry ice/EtOH 
- Store aliquots at -80°C 
 
3.7.2. Transformation of plasmid in HB101 E.coli cells 
 
1st day:  
- Dilute original plasmid Mega Prep 1:100 
- Mix 45 µl HB101 E.coli + 5 µl plasmid (1:100 dilution) 
- Incubate 1 min on ice 
- Put in precooled 4 mm cuvette (Biozym)  
- Electroporate: 1.8kV ; 200Ω ; 25µF 
- Add 500 µl LB-Glu (0.02 M) 
- Incubate 1 h 37°C on the shaker 
- Centrifuge 3 min 3000 rpm in microcentrifuge tube 
- Discard, plate 100 µl on two plates LB-Amp (70 µl + 30 µl) 
- Put plates upside down in the incubator over night 
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2nd day:  
- Pick 1 colony and add to 400 ml LB-Amp (1 µl/ml Amp) 
- Incubate bacterial cells in the shaker over night 37°C 
 
3.7.3. Mega Prep (according to Qiagen) 
 
3rd day:  
- Harvest bacterial cells by centrifugation at 6000 rpm 10 min 4°C 
- Screw the QIAfilter Cartridge onto a 45 mm neck glass bottle and connect it to 
a vacuum score 
- Resuspend bacterial pellet in 50 ml P1 Buffer 
- Add 50 ml P2, mix gently by inverting 4-6 times and incubate on RT 5 min 
- Add 50 ml Buffer P3, mix immediately by inverting 4-6 times, mix well until 
white, fluffy material has formed 
- Pour lysate into QIAfilter Cartridge and incubate at RT 10 min 
- Switch on vacuum source; after all liquid has been pulled through, switch off 
vacuum source 
- Add 50 ml Buffer FWB2, switch on vacuum source 
- Equilibrate Quiagen tip by applying 35 ml Buffer QBT 
- Apply the filtered lysate onto Quiagen tip, allow it to enter the resin by gravity 
flow 
- Wash the tip with 200 ml Buffer QC 
- Elute DNA with 35 ml with QF 
- Precipitate DNA by adding 24.5 ml RT isopropanol, mix and centrifuge 4°C 
4000 rpm 60 min 
- Wash the pellet with 7 ml RT 70 % EtOH, centrifuge 15 min 4°C 4000 rpm, 
carefully decant supernatant 
- Air dry pellet 10-20 min, redissolve DNA in 400-500 µl H2O 
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3.8. ELISA 
 
Reagents 
2x carbonate buffer      120 mM Na2CO3 
                                           80 mM NaH 
                                           pH 9.6, aliquot and store at -20° C 
 
Elisa buffer (EP)           1x PBS 
                                     2 % Tween 
                                     2 % Hammelserum (HS) 
 
Washing buffer             1x PBS 
                                      0.05 % Tween  
                                      pH 7.4  
 
Elisa substrate             10 mg o-Phenylendiamin  
                                               10 ml phosphate buffer- citrate buffer pH 5.0   
 10 µl H2O2 (Sigma) 
 
- Coat the plates with antibody: γ GP2 (dilution 1:3000 in carbonate buffer pH 
9.6) 50 µl/well and incubate 2 days 4°C or 24 hours at RT. (Carbonate buffer 
can only be used for 2 Weeks) 
- Dilute supernatants 1:3 (50 µl +100 µl) in Elisa buffer (EP) 
- Pipette 50 µl of the diluted sample on coated plate                                            
alignment on the plate: 1. row: Blanc, 2. -12. raw samples (including positive 
control) 
- Incubation 2 h 37°C in wet chamber 
- Wash 4x with washing buffer  
- Add 50 µl antigen-specific antibody (γ KP2) per well, diluted: 1:5000 in EP 
- Incubation for 1 h 37°C in the wet chamber 
- 4x washing with washing buffer 
- add 50 µl anti-rabbit IgG-POX-conjugate (1:5000) (Amersham, NA 934, Batch) 
- Incubation for 1 h 37°C in the wet chamber 
- 4x washing with washing buffer 
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- Add 50 µl Elisa substrate per well 
- Incubation 30 min protected from light  at room temperature 
- Stop the reaction by adding 100 µl 2N H2SO4 per well 
- Measurement in ELISA Reader ELX 808/KC Junior 490 nm/ reference filter 
630 nm 
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3.9. Focus assay 
 
Reagents 
Blocking Solution              PBS 7.4  
                                          5 % Hammelserum (HS) 
 
Antigen (Ag) buffer           PBS 7.4  
                                         0.2 % Tween  
                                         3 % HS 
 
Conjugate buffer              TBS  
                                         0.2 % Tween  
                                         3 % HS 
 
Substrate                      
= Sigma Fast® Fast Red TR/Naphtol AS-MX (#F -4648 = 1ml tablet)  
 
Infection  
 
1st day:  
- Seed 1x105 BHK-21 cells per well (24 well plate) 
 
2nd and 3rd day:  
- Wash with 0.5 ml infection medium 
- Make dilutions of the virus (TBEV) with medium for infection (10-1-10-10) and 
add 200 µl of every dilution (1st row of plate  = cell control) 
- Incubation: 3-4 h 37°C, 5 % CO2 
- Remove virus suspension and cover cells with 1 ml 3 % CMC-Overlay in 
medium for infection. (Stock: 6 % CMC in medium for infection 1:1 diluted with 
fresh medium of infection) 
- Incubation: BHK-21: 50-55 h, 37°C, 5 % CO2 (attention: avoid abrasions) 
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4th day:  
- Remove overlay and wash cells 2-3x with PBS (pH 7.4), 0.5 ml/well until 
overlay is totally washed off 
- Fix cells with acetone methanol 1:1, 0.5 ml/well, 10 min -20°C 
- Wait until cells are dry (dry plates can be stored at 4°C for 1-2 days) 
- Blocking: 0.5 ml/well  with Blocking Solution, 30 min room temperature 
- Add 1st antibody: γ KP2 diluted 1:5000 in Ag-buffer, 200 µl/well; incubation for 
1 h 37°C 
- Wash 2x with Ag-buffer, 0.5 ml/well; 3. washing step with conjugate buffer, 0.5 
ml/well 
- Add 2nd antibody: Goat anti-rabbit-IgG-AP (AP = alkalic phosphatase; Sigma # 
A-3812) diluted 1:400 in conjugate buffer and add 200 µl/well; incubation for 
45 min at RT 
- Wash 2x with conjugate buffer: 0.5 ml/well 
- Add substrate, 200 µl/well; incubation for 5-10 min RT 
- Stop of the reaction: remove substrate and wash with ddH2O 0.5 ml/well 
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3.10. Isolation of genomic DNA from cells 
 
Reagent 
Proteinase K lysis buffer          50 mM Tris/HCl pH 8.0 
100 mM NaCl 
100 mM EDTA pH 8.0 
1 % SDS 
 
Proteinase K                            Stock solution (20 mg/ml) proteinase K in H2O 
 
CIA                                           24 vol. chloroform 
1 vol. isoamylalcohol 
 
TE                                            10 mM Tris/HCl pH 8.0 
1 mM EDTA pH 8.0 
 
- Prepare cell pellets by centrifugation of cells, wash the pellet once with PBS 
- Digest cell pellets in 500 µl Proteinase K lysis buffer supplemented with 3 µl 
Proteinase K at 60° C, 2 h – over night 
- Add 500 µl CIA, invert the solution for 5-10 min and centrifuge for 10 min at 
14000 rpm RT 
- Transfer supernatant into a new tube. Precipitate DNA by adding 1 vol. 
isopropanol, invert solution for 3 times and centrifuge for 10 min at 14000 rpm  
- Remove the supernatant and wash the DNA pellet once by adding 500 µl 70 
% ethanol, centrifuge for 5 min at 14000 rpm RT 
- Remove ethanol and air-dry the DNA pellet at RT 
- Resuspend DNA in 70 µl TE 
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3.11. Common reagents and stock solutions 
 
20 % (w/v) APS 
20 g ammoniumpersulfate 
Add H2O to 100 ml 
Store aliquots at -20°C 
 
10x phosphate buffered saline (PBS) 
1.4 M NaCl 
25 mM KCl 
81 mM Na2HPO4 x 2 H2O 
15mM KH2PO4 
pH 7.3 
 
100 mM PMSF 
100 mM phenylmethylsulfonylflourid in 2-propanol 
store at 4°C 
 
6x sample buffer for agarose gels 
0.25 % (w/v) bromphenol blue 
0.25 % (w/v) xylene cyanol FF 
30 % (v/v) glycerol in H2O 
store at 4°C 
 
10x TBE 
890 mM Tris 
890 mM boric acid 
20 mM EDTA 
add H2O to 1 litre 
pH 8.0-8.3 
autoclave 
 
1x TBST 
10 mM Tris/HCl, pH 8 
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150 mM NaCl 
0.05 % Tween 20 
 
10x Trypsin/EDTA (SIGMA)  
Working solution is diluted in sterile PBS and stored at 4°C 
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4. Results 
 
4.1. IFNβ mRNA expression is TBEV RNA replication dependent 
 
Innate immunity is important and necessary to detect viral spread and replication. 
The cell is able to recognize the presence of viruses by pathogen recognition 
receptors (PRRs). When an invading virus is detected, PRRs activate various 
signalling pathways, which lead to the induction of latent transcription factors and 
moreover to the production of type I interferons (IFNs) (Saito and Gale 2007). 
To investigate if and when IFNβ mRNA induction takes place in the cell we infected 
mouse macrophages (RAW cells) with TBEV and isolated cytoplasmic RNA at 
multiple time points. Poly I-C (pIC), a synthetic double stranded RNA, is known as an 
efficient inducer of IFNs (Randall and Goodbourn 2008) and was therefore used as 
positive control in the experiment. Little IFNβ mRNA was detectable 12 hours post 
infection, whereas after 24 hours a high induction was measured (Fig. 7). To test 
whether viral surface glycoproteins play a role in the induction of type I IFNs or viral 
RNA replication, we treated the cells with formalin (FA) inactivated virus or 
recombinant subviral particles (RSPs), which both cannot replicate. After 24 hours no 
type I IFN mRNA was monitored in these cells, indicating that IFNβ expression 
depends on viral RNA replication.   
 
Results 
 - 60 -
 
Fig. 7. TBEV infection induces IFNβ mRNA induction 
RAW cells were infected with TBEV and treated with formalin (FA) inactivated virus and recombinant 
subviral particles (RSPs) for 0, 4, 8, 12 and 24 hours. Cytoplasmic RNA was isolated and the relative 
amount of IFNβ mRNA was determined by quantitative PCR and normalized to the house keeping 
gene gapdh. Poly I-C (pIC) was used as a positive control (1 µg/ml). 
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4.2. TBEV RNA replication mediates type I IFN activation 
 
The interferon regulatory factor 3 (IRF3) is a central transcription factor that is 
involved in the activation of type I IFNs. IRF3 was shown to play a crucial role in the 
activation of IFNα/β and subsequent control of virus replication by most RNA viruses 
like other members of the family Falviviridae (Daffis, Samuel et al. 2007). Here, we 
wanted to analyse the role of IRF3 in activation of type I IFN mRNA and control of 
virus replication. 
We infected wild-type and IRF3 deficient mouse embryonic fibroblasts (MEFs) with 
TBEV and monitored virus replication by staining infected cells with a polyclonal 
antibody raised against TBEV (Fig. 8) and by measuring viral proteins by ELISA in 
the supernatant of infected cells (Fig. 9). 
Cells that are deficient in IRF3 showed a strong increase in virus replication, which is 
shown by amplified viral antigen in the supernatant at MOI 1 and MOI 10 24 hours 
after infection. According to the export of virus to the supernatant, most IRF3 
deficient cells were stained positive for TBEV already 24 hours after infection, while 
positive wild-type cells were only visible 48 hours post infection. 
 
 
 
Fig. 8. TBEV replicates in IRF3-/- cells 
Wild-type (wt) and interferon regulatory factor 3 (IRF3) deficient mouse embryonic fibroblasts (MEFs) 
were infected with TBEV multiplicity of infection 1 (MOI 1) and MOI 10 and left untreated (Mock). Cells 
were fixed with acetone methanol after 48 h and immunofluorescence staining with a polyclonal 
antiserum against TBEV was performed.  
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Fig. 9. Replication of TBEV is elevated in IRF3 -/- MEFs 
Supernatant from cells (wt/IRF3 -/-) infected with MOI 1 and MOI 10 was harvested after 48 h and 
subjected to ELISA measuring virus protein. 
 
 
 
We further analysed the correlation between virus replication and type I IFN mRNA 
expression in these cells. We infected cells with TBEV MOI 1. At the indicated time 
points we isolated total RNA and measured the absolute amount of viral RNA copies 
(Fig. 10) and relative induction of IFNβ mRNA (Fig. 11) by quantitative real-time 
PCR. Again, virus replication was only measured in IRF3 deficient cells, in wild-type 
cells the input RNA measured at 2 hours post infection did not increase. The virus 
started to replicate between 8 and 24 hours. This is also the time frame where IFNβ 
mRNA expression is activated in wild-type cells. In these cells the virus did not 
replicate which was mediated by type I IFNs. This gives another indication that virus 
RNA replication but not the input RNA is a central mechanism in the activation of 
IFNα/β expression. 
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Fig. 10. TBEV replication occurs in IRF3 -/- cells 
Wt MEFs and IRF3 -/- cells were infected with TBEV at MOI 1. The cytoplasmic RNA was isolated 
after 0, 2, 8 and 24 h of infection and reverse transcribed. The amount of RNA was measured by real-
time PCR and was shown in the number of RNA copies post infection. 
 
 
 
Fig. 11. TBEV infection induces IFNβ mRNA in wt MEFs 
Wt MEFs and IRF3 -/- cells were infected with TBEV at MOI 1. The cytoplasmic RNA was isolated 
after 0, 2, 8 and 24 h of infection, reverse transcribed and subjected to quantitiative real-time PCR 
measuring IFNβ expression normalized to the house keeping gene gapdh. 
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4.3. A TBEV replicon is able to replicate in cells deficient in IRF3 
 
In the previous experiments we showed that replication of the RNA virus TBEV leads 
to type I IFN mRNA expression. To analyze which parts of the virus replication cycle 
contribute to IFNα/β induction, we used TBEV RNA constructs and electroporated 
them into wild-type mouse embryonic fibroblasts (MEFs). On the one hand we 
electroporated the replicon C17 (Fig. 12), which is a derivative of full-length infectious 
cDNA clone of TBEV strain Neudoerfl. In this mutant almost the complete structural 
protein coding region is removed, except the parts coding for the first 17 amino acid 
residues of protein C and the interior signal sequence at the carboxy terminus of 
protein E. This RNA is a so called replicon, a RNA molecule defined by its property to 
replicate in host cells; however, due to the lack of structural proteins, unable to infect 
neighbouring cells. The C17 replicon RNA can replicate and translate to wild-type 
levels. On the other hand we transfected a replication deficient mutant (dBSSH) (Fig. 
13) into MEFs. dBSSH exhibits a partial deletion in NS5, the RNA polymerase, and 
therefore cannot replicate (Kofler, Hoenninger et al. 2006). 
 
 
 
 
 
Fig. 12. Schematic drawing of C17  
The nucleotide sequence between position 183 and 2386 (corresponding to amino acid residue 18 of 
protein C and 471 of protein E) of the wild-type TBEV genome was replaced by an artificial sequence 
that includes a multiple cloning site (MCS) (Kofler, Hoenninger et al. 2006). 
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Fig. 13. dBSSH 
The clone contains all structural (C, prM and E) and non-structural (NS) (NS1-NS5) proteins of the 
wild-type TBEV genome, but maintains a partial deletion in the NS5 protein, which provides the RNA- 
dependent RNA polymerase. 
 
 
 
 
 
Fig. 14. NK4 
NK4 is an infectious whole length clone of TBEV strain Neudoerfl. 
 
 
In previous experiments we showed that TBEV can only replicate efficiently in cells 
that are unable to produce type I IFNs like IRF3 -/- cells (Fig. 8-11). Therefore, we 
electroporated the virus constructs in wild-type and IRF3 deficient cells and 
monitored for replication.  
3, 8, 24 and 48 hours post electroporation the cytoplasmic RNA of the cells was 
isolated and the amount of virus RNA copies was determined by quantitative real- 
time PCR (Fig. 15A). After 24 hours the number of C17 RNA copies in IRF3 -/- cells 
was higher than in wt MEFs indicating that the construct replicated only in this cell 
line. As expected, the replication deficient dBSSH RNA was decreased in wt and 
IRF3 knock out (ko) cells. Moreover, we confirmed this result by immunofluorescence 
staining. After cells were electroporated with C17, we stained them with a polyclonal 
antiserum against TBEV. The pictures showed a few positive cells in both cell lines 
after 24 hours whereas after 48 hours the C17 clone was just detected in IRF3 ko 
cells (see Fig. 15B). 
IFNα/β signalling is important to defend the host from pathogens and we proved that 
the transcription factor IRF3 plays a key role in controlling viral replication. IRF3 -/- 
MEFs do not have the important transcription factor and therefore C17 can replicate 
in this cell line.  
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Fig. 15. C17 is able to replicate in IRF3 -/- MEFs 
(A) C17 and dBSSH RNA were electroporated into wt MEFs and IRF3 -/- cells. The cytoplasmic RNA 
was isolated after 3, 8, 24 and 48 h. The amount of RNA was measured by real-time PCR and shown 
in the number of RNA copies post electroporation. (B) Replication of C17 in IRF3 deficient MEFs was 
also monitored by immunofluorescence. Cells were fixed with acetone methanol 48 h post 
electroporation and immunofluorescence staining with a polyclonal antiserum against TBEV was 
performed. 
 
 
In principal, electroporation of the RNA constructs into the MEFs was possible. 
However, immunofluorescence staining showed only 30 % positive cells in IRF3 
deficient cells 48 hours post electroporation (see Fig. 15B), indicating that the 
electroporation efficiency was very low. The electroporation method we used was a 
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standard method used in our laboratory, established to electroporate BHK-21 cells. 
Therefore, we also tried to transfect the RNA into cells with a lipid based transfection 
reagent, Transmessenger Transfection Reagent (Qiagen), which is optimized for 
RNA transfection. To determine the efficiency we electroporated and transfected C17 
into IRF3 -/- cells in parallel and compared the transfection efficiency of these two 
methods by immunofluorescence staining. After 48 hours 40 % positive cells were 
detected in cells that were electroporated, while with transfection only 10-20 % 
positives were monitored (Fig. 16). Consequently, we continued further work by 
electroporating viral RNA constructs. 
 
 
 
 
Fig. 16. Electroporation vs. transfection 
C17 RNA was either electroporated or transfected with Transmessenger Transfection Reagent in IRF3 
-/- MEFs. Cells were fixed with acetone methanol after 48 h and immunofluorescence staining with a 
polyclonal antiserum against TBEV was performed.  
 
 
To enhance electroporation efficiency we tested further electroporation conditions.  
On the one hand C17 replicon RNA was electroporated with 1.8 kV, 200 Ω, 25 µF, 2 
pulses (method 1) into wt MEFs. This condition is suggested and optimized for the 
electroporation of RNA into BHK-21 cells. On the other hand C17 was electroporated 
with 0.270 kV, Ω none, 960 µF (method 2), a method suggested for the 
electroporation of MEFs.  
(Protocol: http://www.bio-rad.at/LifeScience/pdf/Bulletin_3112_132.pdf).  
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After the indicated time points the cytoplasmic RNA was isolated, reverse transcribed 
and the amount of RNA copies was analyzed in quantitative real-time PCR (Fig. 17). 
Finally, no difference between these two methods was monitored and the established 
electroporation method (method 1) was used for following experiments. 
 
 
 
 
 
Fig. 17. Testing of two electroporation methods 
C17 was electroporated into MEFs in two different ways, cytoplasmic RNA was isolated after 3, 8, 24 
and 30 h. The amount of RNA was determined by quantitative PCR and shown in the number of RNA 
copies after electroporation.  
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4.4. Endogenous type I IFN mRNA expression is not detectable 
after electroporation of viral RNA constructs 
 
We showed that TBEV infection leads to the activation of a signal-transduction 
pathway leading to the activation of type I IFNs (Fig. 11). In Figure 15 it was 
monitored that the replicon C17 is able to replicate in IRF3 deficient cells, but not in 
wild-type cells. This goes in line with infection of these cells (Fig. 9-10). Now we 
wanted to detect and compare the production of IFNα/β by electroporating the self 
replicating replicon C17 and the replication deficient dBSSH into wild-type MEFs. 
Cytoplasmic RNA was isolated at the indicated time points, the RNA was reverse 
transcribed and the relative induction of type I IFN mRNA (pan IFN alpha, alpha 4) 
was analyzed in quantitative real-time PCR. The genes of interest were normalized to 
an endogenous control, a housekeeping gene (Ube2d2). pIC, a synthetic double 
stranded RNA, which induces IFNs, was used as positive control. The cells were 
stimulated for 8 and 24 hours with 1 µg/ml pIC.  
After 8 hours an induction of IFNs was measured in cells treated with pIC, but after 
24 hours numbers of cells had died and no mRNA was detected. In cells 
electroporated with C17 and dBSSH no induction of pan IFN alpha and alpha 4 
mRNA was determined after 3, 8, 24 and 48 hours post electroporation (Fig. 18).  
Since years it has been known that cells in culture respond to viruses by initiating a 
complicated signaling cascade, which leads to the production of type I IFNs (Decker, 
Stockinger et al. 2002). Therefore it was either a problem of electroporation efficiency 
or of detection limit, that no endogenous IFN mRNA could be determined. To 
address these problems we used a reporter assay system to increase the sensitivity 
of the assay. 
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Fig. 18. C17 and dBSSH were electroporated into wild-type MEFs. The cytoplasmic RNA was isolated 
3, 8, 24 and 48 h post electroporation. The amount of IFN alpha mRNA and alpha 4 mRNA was 
measured by real-time PCR; pIC (1 µg/ml) was used as a positive control.  
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4.5.    Activation of the IFN beta promoter by TBEV genome 
constructs 
 
To analyze mechanisms of type I IFN induction by replicating virus RNA we 
transfected self replicating RNAs (C17) or viral RNA deficient in replication (dBSSH) 
into mouse cells (Fig. 15A). Transfection of the individual constructs was successful; 
however, we were not able to detect endogenous type I IFN mRNA expression by the 
electroporation of replicating viral RNAs (Fig. 18). Therefore, we established a 
luciferase assay for the activation of the IFN beta promoter by TBEV in HEK 293T 
cells. We were kindly provided with a plasmid containing the firefly luciferase under 
control of the IFN beta promoter, named p125-Luc (provided by Takashi Fujita). For 
standardization we used a plasmid that constitutively expressed Renilla luciferase 
(pRLN-Null).  
Before we started the experiment we optimized the transfection conditions for DNA 
and RNA and compared diverse transfection reagents. 293T cells were utilized for 
the establishment, because they are known to be easily transfected. Plasmid DNA 
expressing GFP (pIRES-EGFP) and RNA (Replicon C17) were transfected on the 
one hand with Transmessenger Reagent (Qiagen) and on the other hand with 
Lipofectin (Invitrogen) (see Fig. 19).  
The pictures of GFP transfected living cells were taken 24 hours after transfection, 
whereas RNA transfected cells were fixed with acetone methanol and 
immunofluorescence was performed 48 hours post transfection. Finally, hardly a 
difference between these two methods was monitored. When GFP was transfected 
with Transmessenger (Qiagen) and Lipofectin (Invitrogen) approximately 10 % of the 
cells were positive, whereas the transfection of C17 with these two transfection 
reagents resulted in nearly 50 % positive cells. Transmessenger Reagent (Qiagen) is 
optimized for RNA according to the manufacturer’s instructions. On the contrary, 
Lipofectin (Invitrogen) is suggested to be used for transfection of DNA. 
Consequently, we decided to continue our work referring to the manufacturer’s 
instructions. 
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Fig. 19. Comparison between transfection methods. 
GFP Plasmid (pIRES-EGFP) (A) and C17 RNA (1 µg/ml) (B) were transfected into 293T cells with 
Transmessenger Reagent and Lipofectin. Whereas GFP was detected 24 h post transfection, 
immunofluorescence of C17 was performed 48 h after transfection.  
 
Firstly, an optimal Renilla control plasmid had to be found. The plasmid that was 
normally used in the lab had a SV 40 promoter, but the problem was that we received 
too high levels of relative light units (RLUs) for standardization with this promoter. 
Therefore, diverse Renilla plasmids (Renilla SV40 Vector, Renilla pRL-Null Vector 
Renilla pRL-CMV Vector (Promega)) were compared and tested (Tab. 1). With the 
plasmids containing SV40 and CMV promoters the RLUs were too high for 
standardization after 48 hours. Therefore, we decided to take the Renilla pRL-Null 
Vector as control plasmid, because the values for the RLUs were the lowest and had 
not increased dramatically 48 hours post transfection. 
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Tab. 1. Expression of Renilla luciferase under control of different promoters 
Various Renilla plasmids were transfected into 293T cells with Lipofectin. After 24 h and after 48 hours 
Renilla luminescence was measured with the luminometer (Victor Light Luminometer, Perkin Elmer).   
hours post transfection 24 48 
Mock (RLUs) 32 46 
Renilla SV40 (RLUs) 21210 542637 
Renilla CMV (RLUs) 542637 202895 
Renilla Null (RLUs) 956 8983 
 
 
A firefly plasmid under the control of an IFNβ promoter, named p125-Luc (provided 
by Takashi Fujita), was used to detect IFNβ promoter activation. The two plasmids 
were co-transfected into 293T cells with Lipofectin. 24 hours later the cells, which 
included the plasmids, were transfected with various viral RNAs (C17, dBSSH, NK4) 
and infected with TBEV (MOI 1). NK4 is a whole length clone of TBEV that contains 
all structural and non-structural proteins of the virus (Fig. 14). Therefore, transfection 
of this RNA into cells leads to the production of viral particles that can spread to 
neighbouring cells. pIC was used as a positive control.  
24 hours post transfection the activity of the firefly and the Renilla luciferase (control 
value) were measured with the luminometer. The values that we received from the 
firefly measurement were standardized to the control data of Renilla. When we 
transfected pIC, C17 and dBSSH into 293T cells a 3-fold induction of the IFN-β 
promoter activity was monitored compared to mock transfected cells 24 hours post 
transfection. Transfection of NK4, the TBEV whole length clone, lead to a higher 
IFNβ induction compared to dBSSH (Fig. 20). dBSSH has a partial deletion in the 
non-structural 5 (NS5) protein, which provides the RNA polymerase and therefore 
cannot replicate. This viral RNA construct is a derivate of NK4 and it can be directly 
compared with the whole length clone. C17 induced also a lower induction of IFNs 
compared to NK4. In fact, C17 is able to replicate in cells, but replication occurs more 
slowly than in NK4 (see Fig. 23A).  
The results indicted that a slower replicating RNA (C17) leads to lower IFN induction. 
Additionally, structural proteins could play a role in IFN induction; however we did not 
test this. Surprisingly, cells infected with TBEV MOI 1 only showed a 4-fold induction 
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of IFNβ. The promoter activity was also lower in infected cells compared to NK4 
transfected cells, but the input RNA levels in cells infected and transfected are not 
comparable. 1 µg transfected RNA contained 1.66x1011 molecules (see methods 
page 45: ″Calculation of the molecular weight of TBEV RNA copies″), whereas with 
infection (MOI 1) 1x105 RNA copies were used. Finally, 1.66x106 more RNA 
molecules were utilized for transfection compared to infection.   
Another explanation for the low levels of type I IFNs could be due to an inhibitory 
effect of viral proteins on the host antiviral response. 
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Fig. 20. Activation of the IFN beta promoter by TBEV genome constructs 
293T cells were co-transfected with IFNβ promoter-luciferase and Renilla luciferase reporter plasmids. 
At 24 h post transfection, cells were either mock transfected or transfected with pIC (control), C17, 
dBSSH and NK4 RNA or infected with TBEV MOI 1. Cells were collected 24 h post transfection/ 
infection for dual luciferase activity (expressed as relative IFNβ promoter activity). Error bars, standard 
deviations were calculated from three independent experiments. 
Results 
 - 75 -
4.6. Activation of endogenous type I IFNs by efficient transfection 
of viral RNA constructs 
 
The luciferase assay showed that transfection of self replicating viral RNA constructs 
lead to the induction of type I IFNs. We still wanted to know the effect on the 
endogenous IFNα/β activation, but as monitored in Figure 19 transfection efficiency 
was very low with Lipofectin (Invitrogen) and Transmessenger Reagent (Qiagen). 
When DNA was transfected only 10 % of the cells were positive, whereas 
transfection of RNA lead to approximately 50 % positive cells.   
Consequently, a very promising transfection reagent, called Lipofectamin 2000 
(Invitrogen), was tested. We compared the transfection efficiency of DNA expressing 
GFP in 293T cells by using various ratios of Lipofectamin 2000 and Lipofectin to DNA 
as it was proposed in the manufacturer’s instructions (Fig. 21). A huge difference can 
be seen between these two methods 24 hours post transfection. With Lipofectamin 
DNA was transfected more efficiently than with Lipofectin. Approximately, 20 % of the 
cells expressed GFP after transfection with Lipofectin, whereas more than 80 % were 
positive after transfection with Lipofectamin 2000, when a ratio of 1:5 was used (GFP 
(µg):Transfection Reagent (µl)).  
Finally, we tested if transfection with Lipofectamin 2000 of C17 into mouse cells 
(L929) is also more efficient than transfection with Lipofectin. L929 cells are an 
established cell line and a very useful tool to study innate immune answers. They 
express most of the receptors, which play an important role in innate immunity. When 
comparing the two transfection reagents, transfection of C17 with Lipofectin resulted 
in approximately 20 % positive mouse fibroblasts, while transfection with 
Lipofectamin 2000 lead to more than 60 % positive cells (Fig. 22). Therefore, 
Lipofectamin 2000 was used for further transfection experiments.  
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Fig. 21. Comparison of transfection methods by transfecting DNA  
GFP was transfected into 293T by varying the ratios of the transfection reagents (Lipofectin and 
Lipofectamin 2000). Pictures of living cells were taken 24 h post transfection. 
 
 
 
 
 
 
Fig. 22. Comparison of transfection methods by transfecting viral RNA constructs  
C17 was transfected into L929 cells with the ratio 1:5 (C17 (µg):Transfection Reagent (µl)). Cells were 
fixed with acetone methanol after 48 h and immunofluorescence staining with a polyclonal antiserum 
against TBEV was performed.  
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4.7.      Transfection of viral RNA leads to the induction of IFN alpha 4  
 
Viral infection leads to type I IFN expression and to the activation of the host’s innate 
immune system. In our study we were interested, which part and mechanism of the 
viral RNA induces IFNα/β and therefore transfected various viral constructs (C17, 
dBSSH, NK4). In previous experiments we electroporated RNA and tried to measure 
type I IFN production. We were not able to detect IFN mRNA by quantitative PCR 
because electroporation efficiency was low and IFN induction under detection limit. 
Therefore, we performed another experiment and transfected the viral RNA 
constructs in mouse fibroblasts (L929 cells) with Lipofectamin 2000, which 
transfected cells more efficiently. We also infected these cells with TBEV MOI 10. 
Total RNA of the transfected/infected L929 cells was isolated, reverse transcribed 
and the induction of IFN alpha 4 mRNA (Fig. 23B) compared to untreated cells was 
quantified by real-time PCR. By transfecting viral RNA with Lipofectamin 2000 an 
induction of IFN α4 mRNA could be shown. The transfection of NK4 lead to higher 
IFN α4 production compared to the transfection of C17 and dBSSH. dBSSH, which is 
a derivate of NK4 and therefore directly comparable with the whole length clone only 
showed a 20-fold IFN α4 induction, whereas NK4 transfection induced 6 times more 
mRNA. C17 transfection also caused IFN α4 mRNA production and lead to a 60-fold 
induction.  
The transfection efficiency was monitored with immunofluorescence 32 hours post 
transfection (see Fig. 23A). With NK4 and C17 a few positive cells were visible, 
whereas with dBSSH no replication was detected with immunofluorescence staining. 
Interestingly, the cells that were infected with TBEV (MOI 10) nearly all appeared 
positive 32 hours post infection, while IFN α4 mRNA expression was very low. 
Surprisingly, infection of cells with TBEV did not show a high IFN expression 
compared to transfection with NK4, although nearly all cells were positive in 
immunofluorescence staining (see Fig. 23A).  
The results suggested that RNA replication is important for viral recognition and for 
induction of IFNs in innate immunity. Moreover, it seems that the type I IFN pathway 
can be somehow suppressed by infection with TBEV. 
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Fig. 23. Endogenous IFN α4 expression by transfection of TBEV RNA  
L929 cells were transfected with NK4, C17, and dBSSH (Lipofectamin 2000) and infected with MOI 
10. 32 h post transfection/infection cells were stained with immunofluorescence (A). Cytoplasmic RNA 
was isolated and the amount of alpha 4 mRNA was determined by real-time PCR 32 h post 
transfection/infection (B). 
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4.8. TBEV interferes with the IRF3 pathway by inhibiting the 
induction of IFNs 
 
In general, flaviviruses have not been shown to cause a non-specific blockade on the 
IRF3 pathway and therefore inhibiting IFN production. However, WNV has developed 
a mechanism to avoid the transcriptional activity of IRF3. Human cells that are 
infected with WNV show a delayed activation of IRF3, 12 to 18 hours post infection. 
Consequently, the virus is able to replicate unchallenged by the host cell by evading 
detection at early times post infection (Fredericksen, Smith et al. 2004). 
We supposed that TBEV has evolved similar strategies to escape the host immune 
system, because we could hardly detect an induction of type I IFNs in infected 293T 
(see Fig. 20) and L929 cells (Fig. 23B). Therefore, we analysed if TBEV somehow 
inhibits the production of IFNα/β and can replicate in the cell without being combated 
by the host’s immune system. Firstly, L929 cells were infected with the virus (MOI 1, 
MOI 10) and mock infected. After 24 hours the total RNA was isolated and 
expression of IFN alpha 4 mRNA and pan IFN alpha mRNA were determined by real-
time PCR. As shown in Fig. 22 an induction of IFN alpha 4 mRNA (Fig. 24A) and pan 
IFN alphas (Fig. 24B) could be monitored 24 hours post infection. However, infection 
with MOI 10 lead to 10 times higher levels of alpha 4 mRNA compared to infection 
with MOI 1 (Fig. 24B).  
To monitor the effect of the inhibition of type I IFN expression on downstream 
effectors functions of IFNs we analysed the expression of a classical IFN target gene. 
Interferon-γ (IFN-γ)-inducible protein-10 (IP-10), a member of the C-X-C sub-family of 
chemokines, is a highly inducible gene. IP-10 is known to stimulate monocytes, 
natural killer and T-cell migration in response to IFN-γ (Singh, Venkataraman et al. 
2007). We detected the induction of IP-10 mRNA with quantitative PCR to show the 
innate immune response of the host after infection with TBEV. 24 hours post 
infection, IP-10 mRNA levels were clearly elevated (Fig. 24C). Whereas with MOI 1 
only a ~200-fold induction could be measured, with MOI 10 nearly a 2000-fold 
induction was monitored. Consequently, after infection with MOI 10, 10 times more 
IP-10 mRNA was produced compared to infection with MOI 1. 
The transfection of pIC with Lipofectamin 2000 caused a strong induction of type I 
IFN and IP-10 mRNA levels. We wanted to analyse if TBEV is able to suppress the 
production of this mRNA. Therefore, L929 cells were infected with TBEV MOI 1, MOI 
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10 and mock infected. 8 hours post infection pIC was transfected into TBEV and 
Mock infected cells. After isolating total RNA of these cells, IFN alpha 4, pan IFN 
alpha and IP-10 mRNA levels were determined by quantitative PCR 24 hours after 
infection. When cells were infected with TBEV prior to the transfection of pIC, the 
induction of mRNA was dramatically reduced compared to non-infected cells treated 
with pIC (Fig. 24D, E and F). The inhibitory effect was even more dramatic in cells 
infected with MOI 10.  
Taken together this clearly showed that TBEV was able to inhibit the production of 
IFNs and ISG (IP-10). Also, the multiplicity of infection (MOI) of the virus seems to 
play an important role in the suppression of the host’s immunity. The higher the MOI 
the more TBEV was able to inhibit the production of type I IFNs that are necessary to 
combat replication of the virus.  
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Fig. 24. TBEV can suppress the induction of type I IFNs 
(A-C) L929 cells were infected with TBEV (MOI 1, MOI 10) and Mock infected. Total RNA was isolated 
after 24 h and the amount of alpha 4 mRNA, pan IFN alpha mRNA and IP-10 mRNA was determined 
by real-time PCR.  
(D-F) L929 cells were infected with TBEV (MOI 1, MOI 10) and Mock infected. After 8 h pIC was 
transfected with Lipofectamin 2000. 24 h post infection total RNA was isolated and the amount of 
alpha 4 mRNA, pan IFN alpha mRNA and IP-10 mRNA was determined by real-time PCR.  
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4.9. Inhibition of interferon-stimulated JAK-STAT signalling by 
TBEV 
 
The non-structural (NS) proteins of diverse members of the flaviviruses have been 
identified as IFN antagonists, whose action impaired signalling processes of the JAK-
STAT pathway (Samuel and Diamond 2006). For example, the NS5 protein of Langat 
virus, a member of tick-borne flaviviruses and a close relative of the TBEV strain we 
were using in our studies, has been identified as an antagonist of IFN actions. Langat 
virus was found to resist IFN’s antiviral effects when cells were treated with IFNβ 
after infection was already established (Best, Morris et al. 2005).  
To further analyse the inhibition of the type I IFN pathway by TBEV we examined the 
interaction of the virus with JAK-STAT signal transduction pathways. In general, 
tyrosine phosphorylation of STAT2 and STAT1 occurs after IFNα/β ligation to the cell 
surface receptors. We analysed phosphorylation of STAT1 at Tyr701 by immunoblot 
analyses of infected L929 cell lysates. L929 cells were infected with TBEV MOI 1 and 
MOI 10 for various time points. To monitor the effect of TBEV infection on activation 
of STAT1 infected cells were treated with recombinant IFNβ (Fig. 25).  
STAT1 Y701 phosphorylation was activated by the addition of recombinant IFNβ for 
30 minutes in Mock treated cells. However, cells that were infected prior to IFNβ 
treatment showed a strong reduction after 24 and 48 hours of infection. The 
accumulation of Tyr701-phosphorylated STAT1 in response to IFNβ was inhibited in 
MOI 1 infected cells after 48 hours and already after 24 hours in cells infected with 
MOI 10.   
In addition, cells infected with MOI 10 showed STAT1 phosphorylation after 24 and 
after 48 hours, indicating that the IFN signalling pathway is activated by infection. 
Interestingly we also observed STAT1 Y701 phosphorylation in cells that were 
infected only for 2 hours. At this time point we did not observe type I IFN production 
in previous experiments. Moreover, STAT1 levels had increased with time of 
infection.  
The results clearly demonstrate that TBEV infection leads to the production of type I 
interferons and to activation of the JAK-STAT pathway. However, once TBEV 
established an infection in the host cell interferons cannot mediate their inhibitory 
functions anymore. 
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Fig. 25.  Inhibition of tyrosine701-phosphorylation of STAT1 in response to IFNβ 
Uninfected L929 cells and cells infected with TBEV (MOI 1, MOI 10) for 2, 8, 24, 48 h were treated 
with IFNβ (500 U) for 30 min or left untreated. The cell lysates were examined by Western blotting with 
antibodies to Tyr701- phosphorylated STAT1 (p-STAT1), STAT1 and pan-ERK for loading control. 
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5. Discussion 
 
5.1. Activation of IFNs by TBEV infection 
 
In general, Flaviviruses interact with the host’s immune system and viral infection 
leads to the activation of type I IFN signalling to limit viral replication and spread. The 
host antiviral response depends on the recognition of viral PAMPs by various pattern 
recognition receptors (PRRs) and results in the production of cytokines, which 
promote an antiviral state (Saito and Gale 2007).  
In our study we investigated the induction and role of type I IFNs in TBEV infection. It 
has not been analysed yet, how type I IFN pathways are activated in TBEV infection 
and how the virus interacts with the innate immune system. Therefore, we studied 
the interaction of TBEV with the host’s Interferon system. We were interested on the 
one hand which host cell factors contribute to the control of virus infection and on the 
other hand which parts of the viral replication cycle leads to the activation of host cell 
signalling pathways. We showed that infection of mouse macrophages with a 
replicating wild-type virus leads to a strong up regulation of IFN α/β mRNA (Fig. 7) 
Treatment of the cells with subviral particles (RSP) or formalin inactivated virus did 
not lead to IFN production. This clearly indicated that only replicating intermediates of 
the virus can be recognized by the host cell. 
IFNα/β gene induction takes place downstream of PRRs. For positive-stranded RNA 
viruses like flaviviruses, PKR, TLR3, RIG-I and MDA 5 recognize double-stranded 
RNA in the cytoplasma and endosome. Sensing of foreign molecules by PRRs leads 
to the activation of signalling pathways and subsequent activation of type I IFN and 
proinflammatory cytokines. The transcription factor IRF3 has been shown to play a 
central role in type I IFN activation by various viruses (Fredericksen, Keller et al. 
2008). Therefore, we addressed the question which role IRF3 plays during TBEV 
infection in vitro. Our experiments demonstrated that infection of IRF3 deficient 
mouse embryonic fibroblasts (MEFs) with TBEV resulted in a strong enhancement of 
viral replication, whereas in wild-type cells the virus could not replicate (Fig. 9, 10). 
The virus started to replicate between 8 and 24 hours in IRF3 knock out cells. During 
this time IFNβ mRNA expression is also activated in wild-type cells, where no viral 
replication occurred.  
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Moreover, we analysed important parts of the virus replication cycle, which possible 
contribute to IFNα/β activation by electroporating and transfecting viral RNA 
constructs into different cell lines. Our study revealed that the TBEV replicon C17, 
which has almost all of the structural proteins deleted, was able to replicate efficiently 
in IRF3 deficient mouse cells, whereas the replicon was replication negative in wild-
type cells. When we electroporated the replication deficient TBEV RNA dBSSH, the 
construct was not detected in wild-type and knock out cells, as expected (Fig. 15A). 
The results indicate that viral replication is a central activator of type I IFN 
expression. It was also shown that IRF3 is an indispensable factor in innate immunity 
and a key regulator in the defence against viral replication in TBEV infection. Our 
experiment revealed that IRF3 plays a key role in controlling TBEV spread and 
replication. Importantly, it plays a central role in the activation pathway of IFNβ gene 
transcription. In IRF3 -/- cells TBEV and a TBEV replicon can replicate unchallenged, 
because type I IFN signalling is destroyed. 
Similarly, it was shown that the Flavivirus West Nile Virus (WNV) is an effective 
trigger of IRF3 activation and its antiviral response combats viral spread. IRF3 
deficient mice show a greater WNV burden in the periphery and extended tissue 
tropism compared to wild-type mice after infection with low doses of virus (Daffis, 
Samuel et al. 2007) 
To analyze mechanisms of IFNα/β induction we transfected self replicating RNA or 
viral RNA defective in replication into HEK293 cells and monitored IFNbeta promoter 
activation in a luciferase assay (Fig. 20). The whole length clone of TBEV NK4, lead 
to a robust IFNbeta promoter activation compared to the replication defective 
dBSSH, which induced the promoter only weakly. Interestingly, transfection of the 
TBEV replicon C17 also lead to a very weak IFNβ promoter activation, although it is 
able to replicate. One possible explanation would be the delayed replication of C17 
compared to the full length clone NK4 (see Fig 23A).  
Also, other factors besides replication are important for type I IFN activation. 
Structural proteins could play a role in IFN production. To verify this hypothesis, one 
could transfect cells with various viral RNA constructs, in which different structural or 
non-structural proteins are knocked out and measure IFNα/β activation. We would 
expect different inductions of type I IFNs and this would allow to explore something 
about the importance of the multiple structural and non-structural proteins. For 
example, in Hepatitis C virus (HCV) the core protein, which is one out of three 
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structural proteins, was shown to stimulate the host’s immune system and trigger 
cytokine production via TLR2 (Chang, Dolganiuc et al. 2007). Furthermore, a study 
reported that measles virus (MV) wild-type strains specifically activated cells via 
TLR2, and this was dependent on the expression of the envelope glycoprotein 
hemagglutinin (H). MV that expressed the wild-type H activated TLR-responsive 
genes in monocytes (Bieback, Lien et al. 2002). 
Furthermore, we were able to show endogenous type I IFN expression by 
quantitative PCR after transfecting TBEV RNA constructs into a mouse cell line 
(L929 cells) (Fig. 23). The experiment demonstrated that transfection of a TBEV full 
length clone (NK4) lead to a higher IFNα4 induction than transfection of its derivate, a 
replication deficient construct (dBSSH) did. The IFNα4 mRNA expression of NK4 was 
even 6 times higher compared to that of dBSSH. The transfection of the replicon C17 
caused IFN α4 mRNA activation, but it was two times lower than the IFN induction of 
the whole length clone NK4. These results revealed that viral replication is an 
important factor of type I IFN induction and necessary for the host cell to recognize 
and combat viral structures.  
The exact mechanism how TBEV recognition in the host takes places and how the 
various PRRs are activated has not been investigated yet. As analysed in previous 
studies it seems that diverse RNA structures play an important role in viral 
recognition (Hornung, Ellegast et al. 2006). The group showed that 5’-triphosphate 
RNA directly binds to RIG-I and RIG-I is responsible for the recognition of 5’-
triphosphate RNA. Generally, the mRNAs of flavivirus infecting cells contain 7-
methyl-guanosine cap structures at their 5’ ends. Nevertheless, RNA synthesis leads 
to cytosolic viral RNA intermediates with an uncapped 5’-triphosphate end. It is 
known that flaviviruses start replication with an uncapped 5’-triphosphate end and 
members of this genus were reported as being recognized by RIG-I (Sumpter, Loo et 
al. 2005; Kato, Takeuchi et al. 2006). 
For future studies we are interested in the work with RIG-I and MDA-5 deficient cell 
lines. By infecting them with TBEV and measuring type I IFNs with quantitative real-
time PCR we could prove the importance of the different PRRs for TBEV recognition 
and their influence on IFNα/β activation. 
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5.2. Inhibition of IFNs by TBEV infection 
 
The host antiviral response depends on the rapid recognition of viral PAMPs by 
innate immune cells to promote an antiviral state. Viruses are in the constant need to 
gain immune evading mechanism to escape the host’s immune system. They have 
evolved diverse strategies not to be recognized and to replicate unchallenged by host 
cells.  
Our findings showed only low IFNα/β activation in TBEV infection in mouse (L929) 
and human (HEK 293T) cell lines. Therefore, we investigated if TBEV inhibits IFN 
expression. It is known that pIC, a synthetic dsRNA, leads to type I IFN activation 
(Randall and Goodbourn 2008). We showed that in mouse cells (L929), where TBEV 
infection was already established, IFNα/β induction was lower after pIC treatment 
than in uninfected cells. These results indicate that TBEV interferes with type I 
signalling by inhibiting the activation of IFNα/β to allow replication.   
Fikrig et al. (Arjona, Ledizet et al. 2007) reported in a study that WNV structural 
protein E, which is the first viral molecule to interact with the host, specifically inhibits 
the induction of antiviral cytokines induced by dsRNA. Further research is necessary 
to identify the protein responsible for IFNα/β inhibition in type I IFN signalling by 
TBEV infection. 
In addition to the inhibitory effect of TBEV on type I IFN production we also analysed 
if the virus can interfere with effector functions of IFNs by interfering with the JAK-
STAT pathway. We showed that once the virus established replication in the host cell 
STAT1 phosphorylation is inhibited (Fig. 25). STAT proteins are essential in 
mediating IFNα/β signalling in innate immune responses and are important for the 
host control of viral infections. 
Tick- and mosquito-borne flaviviruses have developed numbers of strategies to avoid 
type I IFN response by their non-structural (NS) proteins, which downregulate 
individual signalling components of the JAK-STAT pathway (Werme, Wigerius et al. 
2008). It was shown that the NS5 protein of Langat virus (LGTV), a member of 
TBEV, interferes with the IFN response by blocking the phosphorylation of JAK1 and 
Tyk2 (Best, Morris et al. 2005). Similarly, the JEV NS5 protein was identified as an 
IFN antagonist that blocks type I IFN signalling of Tyk and STAT1, possibly via a 
PTP-dependent mechanism (Lin, Chang et al. 2006). Other flaviviruses proteins 
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analysed as IFN antagonists include WNV and DENV NS4B (Munoz-Jordan, 
Sanchez-Burgos et al. 2003). 
In summary, we have identified TBEV as a type I IFN antagonist, which interferes 
with the JAK-STAT pathway by blocking STAT1 phosphorylation. Moreover, TBEV 
reduces IFNα/β induction by inhibiting an essential component of the pathway at the 
early beginning of receptor-mediated type I IFN signalling.  
In future work it would be interesting to clarify the exact mechanism of IFNα/β 
signalling and its inhibition by TBEV. In particular, which parts of the virus lead to 
viral recognition and which component is responsible for the virus interference with 
the host’s innate immunity. 
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